

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2017301915 B2

(54) Title
FcRn antibodies and methods of use thereof

(51) International Patent Classification(s)
C07K 16/28 (2006.01) **G01N 33/68** (2006.01)

(21) Application No: **2017301915** (22) Date of Filing: **2017.07.31**

(87) WIPO No: **WO18/023136**

(30) Priority Data

(31) Number (32) Date (33) Country
62/368,770 **2016.07.29** **US**
62/368,803 **2016.07.29** **US**

(43) Publication Date: **2018.02.01**
(44) Accepted Journal Date: **2024.09.12**

(71) Applicant(s)
Momenta Pharmaceuticals, Inc.

(72) Inventor(s)
Ling, Leona E.;Roy, Sucharita;Washburn, Nathaniel;Kehry, Marilyn;King, David J.;Meador III, James;Manning, Anthony;Hillson, Jan

(74) Agent / Attorney
Davies Collison Cave Pty Ltd, Level 15 1 Nicholson Street, MELBOURNE, VIC, 3000, AU

(56) Related Art
US 2016/0194397 A1
US 2015/0118240 A1
WO 2016/123521 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2018/023136 A1

(43) International Publication Date
01 February 2018 (01.02.2018)

(51) International Patent Classification:
C07K 16/28 (2006.01) *G01N 33/68* (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2017/044765

(22) International Filing Date:
31 July 2017 (31.07.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/368,770 29 July 2016 (29.07.2016) US
62/368,803 29 July 2016 (29.07.2016) US

(71) Applicant: **MOMENTA PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Cambridge, MA 02142 (US).

(72) Inventors: **LING, Leona, E.**; 45 Fells Road, Winchester, MA 01890 (US). **ROY, Sucharita**; 7 Shakespeare Street, Tyngsboro, MA 01879 (US). **WASHBURN, Nathaniel**; 543 King Street, Littleton, MA 01460 (US). **KEHRY, Marilyn**; 10440 Rock Creek Drive, San Diego, CA 92131 (US). **KING, David, J.**; 310 Cole Ranch Road, Encinitas, CA 92024 (US). **MEADOR, James, III**; 38 Gryzboska Circle, Framingham, MA 01702 (US). **MANNING, Anthony**; 185 Hancock Street, Unit 2, Cambridge, MA 02139 (US). **HILLSON, Jan**; 1493 Cambridge Street, Cambridge, MA 02139-1047 (US).

(74) Agent: **MEIKLEJOHN, Anita L.**; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: FCN ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

FCRN ANTIBODIES AND METHODS OF USE THEREOF**BACKGROUND**

Therapeutic proteins, e.g., therapeutic antibodies, have rapidly become a clinically important drug class for patients with immunological diseases. Numerous autoimmune and alloimmune diseases are mediated by pathogenic antibodies. For example, many fetal and neonatal immune diseases result from the transfer of maternal antibodies from a pregnant subject, especially a pregnant subject with an immunological disease, to the fetus through the human neonatal Fc receptor (FcRn) in the placenta. There exists a need for novel methods of treating immunological diseases.

10

SUMMARY

In a first aspect, the application features a method of treating a fetal and neonatal alloimmune and/or autoimmune disorder comprising administering an antibody to a pregnant subject, wherein the antibody includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of the sequence X₁GTGSDVGSYNLVS or TGTGSDVGSYNX₂VS, the CDR L2 includes, comprises, consists of, or consists essentially of the sequence GDX₃ERPS or GDSX₄RPS, the CDR L3 includes, comprises, consists of, or consists essentially of the sequence X₅SYAGSGIYV or SSYX₆GSGIYV, the CDR H1 includes, comprises, consists of, or consists essentially of the sequence of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), or NYAMG (SEQ ID NO: 6), the CDR H2 includes, comprises, consists of, or consists essentially of the sequence of SIGASGSQTRYADS (SEQ ID NO: 8), SIGSSGAQTRYADS (SEQ ID NO: 7),

SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS (SEQ ID NO: 41), SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), or TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 includes, comprises, consists of, or consists essentially of the sequence LAZ₅GDSY or LAI₂Z₆DSY.

5 In some embodiments, the antibody includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 0 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 includes, includes, comprises, consists of, or consists essentially of, consists of, or consists essentially of the sequence TYAMG (SEQ ID NO: 4), the CDR H2 includes, comprises, consists 5 of, or consists essentially of the sequence SIGSSGAQTRYADS (SEQ ID NO: 7), or TIGSSGAQTRYADS (SEQ ID NO: 41), and the CDR H3 includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11).

In some embodiments, the subject has a history of having had a previous fetal and neonatal alloimmune and/or autoimmune disorder. In some embodiments, the subject is at risk of having a fetal 0 and neonatal alloimmune and/or autoimmune disorder. In some embodiments, the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia, hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, 5 dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.

In some embodiments, the fetal and neonatal autoimmune and/or autoimmune disorder is hemolytic disease of the fetus and newborn. In some embodiments, the fetal and neonatal autoimmune and/or autoimmune disorder is fetal and neonatal alloimmune thrombocytopenia. In some embodiments, 30 the fetal and neonatal autoimmune and/or autoimmune disorder is congenital heart block.

In some embodiments, treatment reduces the risk of a miscarriage.

In another aspect, the application features a method of treating fetal anemia associated with hemolytic disease of the fetus and newborn, comprising administering an antibody to a pregnant subject, wherein the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable 35 region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR 40 H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the

CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, the method treats the pregnant subject, a fetus of the pregnant subject, and/or a combination thereof.

10 In another aspect, the application features a method of treating an autoimmune disorder, comprising administering an antibody to a pregnant subject. In some embodiments, the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

In some embodiments, the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, the treatment reduces the risk of miscarriage/loss of fetus.

In another aspect, the application features a method of reducing the risk of or reducing the risk of developing an autoimmune or alloimmune disorder, comprising administering an FcRn antibody to a pregnant subject.

5 In some embodiments, the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, 10 15 20 25 30 35 40

polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

In some embodiments, the treatment reduces the risk of miscarriage/loss of fetus.

20 In another aspect, the application features a method of increasing antibody catabolism in a subject, the method comprising administering an antibody to a pregnant subject, wherein the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, increasing antibody catabolism includes, comprises, consists of, or consists essentially of increasing pathogenic antibody catabolism.

In some embodiments, the pathogenic antibody is pathogenic to the mother, the fetus, or both the mother and the fetus.

40 In some embodiments, the antibody is an IgG antibody.

In another aspect, the application features a method of reducing autoantibodies in a subject, the method comprising administering an antibody to a pregnant subject, wherein the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In another aspect, the application features a method of reducing an immune complex-based activation of an immune response in a subject, the method comprising administering an antibody to a pregnant subject, wherein the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, the immune response is an acute or chronic immune response in the subject.

In some embodiments, the acute immune response is activated by a medical condition selected from the group consisting of pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dilated cardiomyopathy, and serum sickness.

In some embodiments, the chronic immune response is activated by a medical condition selected from the group consisting of chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, and antineutrophil cytoplasmic antibody-associated vasculitis. In some embodiments, the chronic immune response is activated by chronic

5 inflammatory demyelinating polyneuropathy.

In some embodiments, the subject has an autoimmune disease. In some embodiments, the autoimmune disease is selected from the group consisting of alopecia areata, ankylosing spondylitis, 10 antiphospholipid syndrome, Addison's disease, hemolytic anemia, warm autoimmune hemolytic anemia, anti-factor antibodies, heparin induced thrombocytopenia (, sensitized transplant, autoimmune hepatitis, hepatitis, Behcets disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, 15 autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, 20 scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

In another aspect, the application features a method of decreasing antibody transport across the placenta of a pregnant subject, the method comprising administering an antibody to a pregnant subject, wherein the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable 25 region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR 30 H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic 35 amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In another aspect, the application features a method of increasing antibody catabolism in a 40 pregnant subject, the method comprising administering an antibody to a pregnant subject, wherein the

antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, 5 consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence 10 LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

15 In some embodiments, the antibody causes a fetal and neonatal alloimmune and/or autoimmune disorder in a fetus in the pregnant subject.

In some embodiments, the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, 20 neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.

In some embodiments, the antibody is an IgG antibody.

25 In another aspect, the application features a method of treating an antibody-mediated enhancement of viral disease in a fetus or a neonate, the method comprising administering an antibody to a pregnant subject, wherein the antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, 30 consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), the CDR H3 includes, comprises, consists of, or consists 35 essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic 40 amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, the viral disease is caused by a virus selected from the group consisting of an alpha virus infection, flavivirus infection, Zika virus infection, Chikungunya virus infection, Ross River virus infection, severe acute respiratory syndrome coronavirus infection, Middle East respiratory syndrome, avian influenza infection, influenza virus infection, human respiratory syncytial virus infection, 5 Ebola virus infection, yellow fever virus infection, dengue virus infection, human immunodeficiency virus infection, respiratory syncytial virus infection, Hantavirus infection, Getah virus infection, Sindbis virus infection, Bunyamwera virus infection, West Nile virus infection, Japanese encephalitis virus B infection, rabbitpox virus infection, lactate dehydrogenase elevating virus infection, reovirus infection, rabies virus infection, foot-and-mouth disease virus infection, porcine reproductive and respiratory syndrome virus 10 infection, simian hemorrhagic fever virus infection, equine infectious anemia virus infection, caprine arthritis virus infection, African swine fever virus infection, lentivirus infection, BK papovavirus infection, Murray Valley encephalitis virus infection, enterovirus infection, cytomegalovirus infection, pneumovirus infection, morbillivirus infection, and measles virus infection.

In some embodiments, the pregnant subject has or is at risk of having a medical condition that 15 activates an immune response in the pregnant subject.

In some embodiments, the medical condition is pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, 20 autoimmune hearing loss, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dialated cardiomyopathy, serum sickness, chronic inflammatory demyelinating polyneuropathy, systemic lupus, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, alopecia areata, ankylosing spondylitis, 25 antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, 30 dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, 35 multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

In some embodiments, the pregnant subject has a history of having had a previous fetus or neonate that had a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, an antibody associated with an immune disease is detected in a biological sample obtained from the pregnant subject.

40 In some embodiments, the biological sample is a blood or urine sample.

In some embodiments, the isolated antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 has a sequence having no more than two amino acid substitutions relative to the sequence of
5 TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 has a sequence having no more than one amino acid substitution relative to the sequence of GDSERPS (SEQ ID NO: 2), the CDR L3 has a sequence having no more than one amino acid substitution relative to the sequence of SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 has a sequence having no more than one amino acid substitution relative to the sequence of
0 TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), or NYAMG (SEQ ID NO: 6), the CDR H2 has a sequence having no more than two amino acid substitutions relative to the sequence of
SIGASGSQTRYADS (SEQ ID NO: 8), SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS (SEQ ID NO: 41),
5 SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), or TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 has a sequence having no more than one amino acid substitution relative to the sequence of LAIGDSY (SEQ ID NO: 11).

In some embodiments, the isolated antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of the sequence X₁TGTGSDVGSYNLVS or
0 TGTGSDVGSYNX₂VS, the CDR L2 includes, comprises, consists of, or consists essentially of the sequence GDX₃ERPS or GDSX₄RPS, the CDR L3 includes, comprises, consists of, or consists essentially of the sequence X₅SYAGSGIYV or SSYX₆GSGIYV, the CDR H1 includes, comprises, consists of, or consists essentially of the sequence of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), or
5 NYAMG (SEQ ID NO: 6), the CDR H2 includes, comprises, consists of, or consists essentially of the sequence of SIGASGSQTRYADS (SEQ ID NO: 8), SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS (SEQ ID NO: 41), SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), or
TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 includes, comprises, consists of, or consists essentially of the sequence LAZ₅GDSY or LAI₆DSY.

30 In some embodiments, the antibody includes, comprises, consists of, or consists essentially of the following six CDRs the CDR L1 of sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 of sequence TYAMG (SEQ ID NO: 4), the CDR H2 of sequence
35 SIGSSGAQTRYADS (SEQ ID NO: 7), or TIGSSGAQTRYADS (SEQ ID NO: 41), and the CDR H3 of sequence LAIGDSY (SEQ ID NO: 11).

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises,
40

consists of, or consists essentially of the sequence DYAMG (SEQ ID NO: 5), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11).

5 In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence NYAMG (SEQ ID NO: 6), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGAQTRYADS (SEQ ID NO: 9) or TIGASGAQTRYADS (SEQ ID NO: 43), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11).

5 In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TYAMG (SEQ ID NO: 4), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGGQTRYADS (SEQ ID NO: 10) or TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11).

5 In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TYAMG (SEQ ID NO: 4), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11).

5 In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence X_1 GTGSDVGSYNX $_2$ VS (SEQ ID NO: 12), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence GDX $_3$ X $_4$ RPS (SEQ ID NO: 13), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence X $_5$ SYX $_6$ GSGIYV (SEQ ID NO: 14), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence Z $_1$ YAMG (SEQ ID NO: 15), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence Z $_7$ IGZ $_2$ SGZ $_3$ QTZ $_4$ YADS (SEQ ID NO: 16), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence LAZ $_5$ Z $_6$ DSY (SEQ ID NO: 17), wherein X $_1$ is T, A, S, or I, X $_2$ is L or I, X $_3$ is S, N,

or T, X₄ is Q, E, or N, X₅ is C, S, I, or Y, X₆ is A or V, Z₁ is E, T, D, or N, Z₂ is S or A, Z₃ is G, S, or A, Z₄ is K or R, Z₅ is I, L, or H, Z₆ is G, S, D, Q, or H, and Z₇ is S or T.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTRYADS (SEQ ID NO: 18), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), and wherein Z₁ is T, D, or N, Z₂ is S or A, Z₃ is G, S or A, and Z₇ is S or T.

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

15 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19).

20 In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSAQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
25 TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPVSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

30 In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
35 GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPVSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
5 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKS
10 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
15 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKS
20 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
25 TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKS
30 WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
35 GNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody has a
sequence having at least 90% identity to the sequence of
EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRF
40 TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG

TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW

5 QQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS

10 GNTASLTISGLQAEDEADYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

15 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
20 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

25 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDEADYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

30 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
35 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,

5 comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPPLAPSSKSTSG
10 GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
20 QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

In some embodiments, the light chain variable region of the isolated antibody includes,

15 comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
20 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,

comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPPLAPSSKSTSGG
25 TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

30 In some embodiments, the heavy chain variable region of the isolated antibody includes,
comprises, consists of, or consists essentially of a sequence having at least 95%, 97%, 99%, or 100%
identity to the sequence of any one of SEQ ID NOS: 20-24.

In some embodiments, the light chain variable region of the isolated antibody includes,
comprises, consists of, or consists essentially of a sequence having at least 95%, 97%, 99%, or 100%
35 identity to the sequence of SEQ ID NO: 19.

In some embodiments, the light chain variable region of the isolated antibody includes,
comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
40 SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYASSYSLTPEQWKSHKSYSCQVTHEGSTVEK

TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of

EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG

5 TAALGCLVKDVFPEPVTWSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

10 In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYFGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQCVTHEGSTVEK

15 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of

EVQLLESGGLVQPGGSLRLSCAASGFTFSYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDVFPEPVTWSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS

20 NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

25 In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYFGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQCVTHEGSTVEKTVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,

30 comprises, consists of, or consists essentially of the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDVFPEPVTWSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

35 In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of

5 QSALTQPASVGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody has the

sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
0 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of

5 QSALTQPASVGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence of

0 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
5 VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

In some embodiments, the antibody binds human FcRn with a K_D of between 1 pM and 100 nM.

In some embodiments, the isolated antibody binds human FcRn with a K_D of less than or equal to that of antibody N026.

30 In some embodiments, the isolated antibody is a monoclonal antibody.

In some embodiments, the isolated antibody is IgG1 or variant thereof.

In some embodiments, the isolated antibody includes, comprises, consists of, or consists essentially of a λ light chain.

In some embodiments, the isolated antibody is a sialylated antibody.

35 In another aspect, the application features an isolated antibody that binds to human FcRn, the isolated antibody comprising: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein (a) the CDR L1 includes, comprises, consists of, or consists essentially of the sequence SDVGSYNL (SEQ ID NO: 47) or VG_YNL (SEQ ID NO: 34), wherein the “_” can be any amino acid, (b) the CDR L2 includes, comprises, consists of, or consists essentially of the sequence GDSE (SEQ ID NO: 35), (c) the

CDR L3 includes, comprises, consists of, or consists essentially of the sequence YAGSGIY (SEQ ID NO: 36), (d) the CDR H1 includes, comprises, consists of, or consists essentially of the sequence TYA (SEQ ID NO: 37), (e) the CDR H2 includes, comprises, consists of, or consists essentially of the sequence SIGASGSQTR (SEQ ID NO: 38) or SI_AS_SQ_R (SEQ ID NO: 39), wherein the “_” can be any amino acid, and (f) the CDR H3 includes, comprises, consists of, or consists essentially of the sequence LAI (SEQ ID NO: 40).

5 In some embodiments, the antibody recognizes the amino acid sequences a) SEQ ID NO: 25_and b) SEQ ID NO: 26 in the human FcRn.

In some embodiments, the antibody binds to an epitope on FcRn comprising at least one, two, 10 three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty amino acids selected from the group consisting of K80, A81, L82, G83, G84, K85, G86, P87, Y88, L112, N113, E115, G129, D130, W131, P132, E133, L135, A136, and Q139 of SEQ ID NO: 30.

In some embodiments, the antibody binds to an epitope on FcRn comprising at least one, two, 15 three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty amino acids selected from the group consisting of K80, A81, L82, G83, G84, K85, G86, P87, Y88, L112, N113, G129, D130, W131, P132, E133, L135, A136, and Q139 of SEQ ID NO: 30.

20 In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of W131 and/or Y88 of SEQ ID NO: 30.

In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of D130W131, W131P132, P87Y88, and/or Y88T89 of SEQ ID NO: 30.

25 In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of G129D130W131, W131P132E133, D130W131P132, P87Y88T89, G86P87Y88, and/or Y88T89L90 of SEQ ID NO: 30.

In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of G129D130W131P132, D130W131P132E133, W131P132E133A134, G128G129D130W131, K85G86P87Y88, G86P87Y88T89, P87Y88T89L90, and/or Y88T89L90Q91 of SEQ ID NO: 30.

30 In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of G129D130W131P132E133, D130W131P132E133A134, W131P132E133A134L315, G128G129D130W131P132, W127G128G129D130W131, G84K85G86P87Y88, K85G86P87Y88T89, G86P87Y88T89L90, P87Y88T89L90Q91, and/or Y88T89L90T91Q92 of SEQ ID NO: 30.

35 In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of T126W127G128G129D130W131, W127G128G129D130W131P132, G128G129D130W131P132E133, G129D130W131P132E133A134, D130W131P132E133A134L135, W131P132E133A134L135A136, G83G84K85G86P87Y88, G84K85G86P87Y88T89, K85G86P87Y88T89L90, G86P87Y88T89L90Q91, P87Y88T89L90T91Q92, and/or Y88T89L90Q91G92L93 of SEQ ID NO: 30.

In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of one or more amino acids within about 3 amino acids or 10 Angstroms of W131, one or more amino acids within about 5 amino acids or 8 Angstroms Y88, or any two sets of amino amino acids, wherein the first set is or includes W131 and the second set is or includes Y88 of SEQ ID NO: 30.

5 In some embodiments, the epitope on FcRn includes, comprises, consists of, or consists essentially of K80, A81, L82, G83, G84, K85, G86, P87, Y88, L112, N113, E115, G129, D130, W131, P132, E133, L135, A136, and Q139.

In some embodiments, the isolated antibody binds to an epitope on β 2-microglobulin comprising at least one amino acid selected from the group consisting of I1, Q2, P32, and V85 of SEQ ID NO: 31.

10 In some embodiments, the isolated antibody includes, comprises, consists of, or consists essentially of the amino acid sequence KSG at positions 66-68 Kabat.

In another aspect, the application features an isolated antibody, comprising: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein (a) the CDR L1 includes, comprises, consists of, or consists essentially of SDVGSYNL, provided it does not comprise TGTGSDVGSYNLVS (SEQ ID NO: 1), (b) the CDR L2 includes, comprises, consists of, or consists essentially of GDSE, provided it does not comprise GDSERPS (SEQ ID NO: 2), (c) the CDR L3 includes, comprises, consists of, or consists essentially of YAGSGIY, provided it does not comprise SSYAGSGIYV (SEQ ID NO: 3), (d) the CDR H1 includes, comprises, consists of, or consists essentially of TYA, provided it does not comprise TYAMG (SEQ ID NO: 4), (e) the CDR H2 includes, comprises, consists of, or consists essentially of SIGASGSQTR, provided it does not comprise SIGASGSQTRYADS (SEQ ID NO: 8), or (f) the CDR H3 includes, comprises, consists of, or consists essentially of LAI, provided it does not comprise LAIGDSY (SEQ ID NO: 11).

In another aspect, the application features an isolated antibody, comprising: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein (a) the CDR L1 includes, comprises, consists of, or consists essentially of TGTGSDVGSYNLVS (SEQ ID NO: 1), wherein no more than six single amino acids are deleted or substituted, provided that no amino acids within the subsequence SDVGSYNL are deleted or substituted, (b) the CDR L2 includes, comprises, consists of, or consists essentially of GDSERPS (SEQ ID NO: 2), wherein no more than three single amino acids are deleted or substituted, provided that no amino acids within the subsequence GDSE are deleted or substituted, (c) the CDR L3 includes, comprises, consists of, or consists essentially of SSYAGSGIYV (SEQ ID NO: 3) wherein no more than three single amino acids are deleted or substituted, provided that no amino acids within the subsequence YAGSGIY are deleted or substituted, (d) the CDR H1 includes, comprises, consists of, or consists essentially of a sequence selected from the group consisting of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), and NYAMG (SEQ ID NO: 6), wherein no more than three single amino acids are deleted or substituted, provided that no amino acids within the subsequence YA are substituted, (e) the CDR H2 includes, comprises, consists of, or consists essentially of a sequence selected from the group consisting of SIGASGSQTRYADS (SEQ ID NO: 8), SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS

(SEQ ID NO: 41), SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), and TIGASGGQTRYADS (SEQ ID NO: 46), wherein no more than three single amino acids are deleted or substituted, and (f) the CDR H3 includes, comprises, consists of, or consists essentially of LAIGDSY (SEQ ID NO: 11), wherein no more than four single amino acids are deleted or substituted, provided that no amino acids within the subsequence LAI are deleted or substituted.

In some embodiments, the CDR L1 includes no more than five (e.g., 4, 3, 2, or 1) single amino acid substitutions or deletions. In some embodiments, the CDR L2 includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR L3 includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR H1 includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR H2 includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR H3 includes no more than three (e.g., 2 or 1) single amino acid substitutions or deletions.

In another aspect, the application features an isolated antibody, comprising: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein (a) the CDR L1 includes, comprises, consists of, or consists essentially of TGTGSDVGSYNLVS (SEQ ID NO: 1), wherein no more than nine single amino acids are deleted or substituted in SEQ ID NO: 1, provided that no amino acids within the subsequences of VG and YNL of SEQ ID NO: 1 are deleted or substituted, (b) the CDR L2 includes, comprises, consists of, or consists essentially of GDSERPS (SEQ ID NO: 2), wherein no more than three single amino acids are deleted or substituted, provided that no amino acids within the subsequence GDSE are deleted or substituted, (c) the CDR L3 includes, comprises, consists of, or consists essentially of SSYAGSGIYV (SEQ ID NO: 3) wherein no more than three single amino acids are deleted or substituted, provided that no amino acids within the subsequence YAGSGIY are deleted or substituted, (d) the CDR H1 includes, comprises, consists of, or consists essentially of a sequence selected from the group consisting of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), and NYAMG (SEQ ID NO: 6), wherein no more than three single amino acids are deleted or substituted, provided that no amino acids within the subsequence YA are substituted, (e) the CDR H2 includes, comprises, consists of, or consists essentially of a sequence selected from the group consisting of SIGASGSQTRYADS (SEQ ID NO: 8), SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS (SEQ ID NO: 41), SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), and TIGASGGQTRYADS (SEQ ID NO: 46), wherein no more than seven single amino acids are deleted or substituted, provided that no amino acids within the subsequences SI, AS, SQ, or R are deleted or substituted or (f) the CDR H3 includes, comprises, consists of, or consists essentially of LAIGDSY (SEQ ID NO: 11), wherein no more than four single amino acids are deleted or substituted, provided that no amino acids within the subsequence LAI are deleted or substituted.

In some embodiments, the CDR L1 includes no more than eight (e.g., 7, 6, 5, 4, 3, 2, or 1) single amino acid substitutions or deletions. In some embodiments, the CDR L2 includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR L3 includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR H1

includes no more than two (e.g., 1) single amino acid substitutions or deletions. In some embodiments, the CDR H2 includes no more than six (e.g., 5, 4, 3, 2, or 1) single amino acid substitutions or deletions. In some embodiments, the CDR H3 includes no more than three (e.g., 2 or 1) single amino acid substitutions or deletions.

5 In some embodiments, the antibody recognizes the amino acid sequences a) SEQ ID NO: 25 and b) SEQ ID NO: 26 in the human FcRn.

In some embodiments, the antibody recognizes an amino acid sequence on FcRn comprising W131 and/or Y88 in SEQ ID NO: 30. In some embodiments, the antibody recognizes an amino acid sequence on FcRn comprising DW, WP, PY, and/or YT in SEQ ID NO: 30. In some embodiments, 10 the antibody recognizes an amino acid sequence on FcRn comprising GDW, WPE, DWP, PYT, GPY, and/or YTL in SEQ ID NO: 30. In some embodiments, the antibody recognizes an amino acid sequence on FcRn comprising GDWP, DWPE, WPEA, GGDW, KGPY, GPYT, PYTL, and/or YTLQ in SEQ ID NO: 30. In some embodiments, the antibody recognizes an amino acid sequence on FcRn comprising GDWPE, DWPEA, WPEAL, GGDWP, WGGDW, GKGPy, KGPYt, GPytl, PYTLQ, and/or YTLTQ in 15 SEQ ID NO: 30. In some embodiments, the antibody recognizes an amino acid sequence on FcRn comprising TWGGDW, WGGDW, GGDWPE, GDWPEA, DWPEAL, WPEALA, GGKGPy, GKGPyt, KGPYtl, GPytlQ, PYTLTQ, and/or YTLQGL in SEQ ID NO: 30. In some embodiments, the antibody recognizes an amino acid sequence on FcRn comprising one or more amino acids within about 3 amino acids or 10 Angstroms of W131, one or more amino acids within about 5 amino acids or 8 Angstroms of 20 Y88, or any two sets of amino acids, wherein the first set is or includes W131 and the second set is or includes Y88 (e.g., Y88 and amino acids around Y88) in SEQ ID NO: 30.

In another aspect, the application features an isolated antibody that binds to human FcRn, wherein the antibody binds to an epitope comprising: (a) a first amino acid sequence comprising at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25); and (b) a second amino acid sequence comprising at least one amino acid of the sequence of FKALGGKGPytl (SEQ ID NO: 26), 25 wherein the antibody inhibits the binding of IgG to human FcRn.

In another aspect, the application features an isolated antibody that binds to human FcRn, wherein the antibody binds to an epitope comprising at least one amino acid in the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25), wherein the antibody binds to at least one of amino acid residues 30 9, 12, or 13 of SEQ ID NO: 25, and wherein the antibody inhibits the binding of IgG to human FcRn.

In another aspect, the application features an isolated antibody that binds to human FcRn, wherein the antibody binds to an epitope comprising at least one amino acid in the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25) in FcRn, wherein the antibody does not bind to a peptide consisting of the sequence GEEFMNFDLKQGT (SEQ ID NO: 27) or to the sequence of EEFMFNFDL 35 (SEQ ID NO: 28), and wherein the antibody inhibits the binding of IgG to human FcRn.

In some embodiments, the epitope includes, comprises, consists of, or consists essentially of at least one amino acid in the sequence of WGGDWPEAL (SEQ ID NO: 29) in FcRn.

In some embodiments, the epitope includes, comprises, consists of, or consists essentially of at least amino acid residue 9 of SEQ ID NO: 25 in FcRn. In some embodiments, the epitope includes, 40 comprises, consists of, or consists essentially of at least amino acid residue 12 of SEQ ID NO: 25 in

5 FcRn. In some embodiments, the epitope includes, comprises, consists of, or consists essentially of at least amino acid residue 13 of SEQ ID NO: 25 in FcRn. In some embodiments, the epitope includes, comprises, consists of, or consists essentially of at least one amino acid of the sequence of FKALGGKGPYTL (SEQ ID NO: 26) in FcRn. In some embodiments, the epitope includes, comprises, consists of, or consists essentially of at least two amino acids of the sequence of FKALGGKGPYTL (SEQ ID NO: 26) in FcRn.

10 In some embodiments, the antibody binds to an epitope comprising at least one amino acid of the sequence of FKALGGKGPYTL (SEQ ID NO: 26) in FcRn, and wherein the antibody inhibits the binding of IgG to human FcRn. In some embodiments, the epitope includes, comprises, consists of, or consists essentially of at least two amino acids of the sequence of FKALGGKGPYTL (SEQ ID NO: 26) in FcRn.

15 In some embodiments, the epitope further includes, comprises, consists of, or consists essentially of at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25) in FcRn.

20 In some embodiments, the antibody binds to at least two amino acids of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25) in FcRn.

25 In some embodiments, the antibody binds to at least one of amino acid residues 9, 12, or 13 of SEQ ID NO: 25 in FcRn.

30 In some embodiments, the antibody binds to at least amino acid residue 9 of SEQ ID NO: 25 in FcRn. In some embodiments, the antibody binds to at least amino acid residue 12 of SEQ ID NO: 25 in FcRn. In some embodiments, the antibody binds to at least amino acid residue 13 of SEQ ID NO: 25 in FcRn.

35 In some embodiments, the antibody binds human FcRn with a K_D of between 1 pM and 100 nM.

40 In some embodiments, the antibody binds human FcRn with a K_D of no more than that of antibody N026.

45 In some embodiments, the antibody is a monoclonal antibody.

50 In some embodiments, the antibody is IgG1.

55 In some embodiments, the antibody includes, comprises, consists of, or consists essentially of a λ light chain.

60 In some embodiments, the antibody is a sialylated antibody.

65 In some embodiments, the antibody is for use in treating a fetal and neonatal alloimmune and/or autoimmune disorder.

70 In some embodiments, the antibody is for use in reducing the risk of developing a fetal and neonatal alloimmune and/or autoimmune disorder.

75 In some embodiments, the antibody is for use in reducing the risk of developing an autoimmune or alloimmune disorder.

80 In some embodiments, the antibody is for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

85 In another aspect, the application features a nucleic acid molecule encoding an isolated antibody of any of the above aspects. In another aspect, the application features a vector comprising the nucleic acid molecule. A host cell may express the isolated antibody, wherein the host cell includes, comprises, 90 consists of, or consists essentially of a nucleic acid molecule or a vector, wherein the nucleic acid

molecule or vector is expressed in the host cell. The host cell may be a Chinese hamster ovary (CHO) cell.

In another aspect, the application features a pharmaceutical composition comprising an isolated antibody of any of the above aspects and one or more pharmaceutically acceptable carriers or excipients.

5 The antibody may be formulated in a therapeutically effective amount.

In another aspect, the application features a method of preparing an isolated antibody of any of the above aspects, the method comprising:

a) providing a host cell comprising a nucleic acid molecule of claim 178 or a vector of claim 179, and

10 b) expressing the nucleic acid molecule or vector in the host cell under conditions that allow for the formation of the antibody.

In some embodiments, the method may further comprise the step of recovering the antibody at a concentration of about 1-100, 1-50, 1-25, 2-50, 5-50, or 2-20 mg/ml.

In some embodiments, the host cell is a CHO cell.

15 In another aspect, the application features a method of treating a fetal and neonatal alloimmune and/or autoimmune disorder comprising administering an antibody to a pregnant subject, wherein the antibody is the antibody of any of the above aspects.

In some embodiments, the subject has a history of having had a previous fetal and neonatal alloimmune and/or autoimmune disorder.

20 In some embodiments, the subject is at risk of having a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia, hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, 25 neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.

In some embodiments, treatment reduces the risk of a miscarriage.

30 In another aspect, the application features a method of treating fetal anemia associated with hemolytic disease of the fetus and newborn, comprising administering the antibody of any of the above aspects to a pregnant subject.

In some embodiments, the method treats the pregnant subject, a fetus of the pregnant subject, and/or a combination thereof.

35 In another aspect, the application features a method of treating an autoimmune disorder, comprising administering the antibody of any of the above aspects to a pregnant subject.

In some embodiments, the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-40 dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating

polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, 5 IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, 10 Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

In some embodiments, the treatment reduces the risk of miscarriage/loss of fetus.

In another aspect, the application features a method of reducing the risk of or reducing the risk of developing an autoimmune or alloimmune disorder, comprising administering the antibody of any of the above aspects to a pregnant subject.

15 In some embodiments, the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, 20 polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

In some embodiments, the treatment reduces the risk of miscarriage/loss of fetus.

25 In another aspect, the application features a method of increasing antibody catabolism in a subject, the method comprising administering to the subject an isolated antibody or a pharmaceutical composition of any of the above aspects.

In some embodiments, increasing antibody catabolism includes, comprises, consists of, or consists essentially of increasing pathogenic antibody catabolism.

30 In some embodiments, the pathogenic antibody is pathogenic to the mother, the fetus, or both the mother and the fetus.

In some embodiments, the antibody is an IgG antibody.

In another aspect, the application features a method of reducing autoantibodies in a subject, the method comprising administering to the subject an isolated antibody or a pharmaceutical composition of 40 any of the above aspects.

In another aspect, the application features a method of reducing an immune complex-based activation of an immune response in a subject, the method comprising administering to the subject an isolated antibody or a pharmaceutical composition of any of the above aspects.

In some embodiments, the immune response is an acute or chronic immune response in the

5 subject.

In some embodiments, the acute immune response is activated by a medical condition selected from the group consisting of pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dilated cardiomyopathy, and serum sickness.

10 In some embodiments, the fetal and neonatal autoimmune and/or autoimmune disorder is hemolytic disease of the fetus and newborn.

15 In some embodiments, the fetal and neonatal autoimmune and/or autoimmune disorder is fetal and neonatal alloimmune thrombocytopenia.

In some embodiments, the fetal and neonatal autoimmune and/or autoimmune disorder is congenital heart block.

20 In some embodiments, the chronic immune response is activated by a medical condition selected from the group consisting of chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

In some embodiments, the subject has an autoimmune disease.

25 In some embodiments, the autoimmune disease is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, 30 inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, 35 rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

In another aspect, the application features a method of decreasing antibody transport across the placenta of a pregnant subject, the method comprising administering to the pregnant subject an isolated antibody or a pharmaceutical composition of any of the above aspects.

In some embodiments, decreasing antibody transport includes, comprises, consists of, or consists essentially of decreasing pathogenic antibody transport.

In another aspect, the application features a method of increasing antibody catabolism in a pregnant subject, the method comprising administering to the pregnant subject an isolated antibody or a pharmaceutical composition of any of the above aspects.

In some embodiments, increasing antibody catabolism includes, comprises, consists of, or consists essentially of increasing pathogenic antibody catabolism.

In another aspect, the application features a method of treating an antibody-mediated enhancement of viral disease in a fetus or a neonate, the method comprising administering to a pregnant subject an isolated antibody or a pharmaceutical composition of any of the above aspects.

In some embodiments, the pathogenic antibody causes a fetal and neonatal alloimmune and/or autoimmune disorder in a fetus in the pregnant subject.

In some embodiments, the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia, hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.

In some embodiments, the antibody is an IgG antibody.

In some embodiments, the viral disease is caused by a virus selected from the group consisting of an alpha virus infection, flavivirus infection, Zika virus infection, Chikungunya virus infection, Ross River virus infection, severe acute respiratory syndrome coronavirus infection, Middle East respiratory syndrome, avian influenza infection, influenza virus infection, human respiratory syncytial virus infection, Ebola virus infection, yellow fever virus infection, dengue virus infection, human immunodeficiency virus infection, respiratory syncytial virus infection, Hantavirus infection, Getah virus infection, Sindbis virus infection, Bunyamwera virus infection, West Nile virus infection, Japanese encephalitis virus B infection, rabbitpox virus infection, lactate dehydrogenase elevating virus infection, reovirus infection, rabies virus infection, foot-and-mouth disease virus infection, porcine reproductive and respiratory syndrome virus infection, simian hemorrhagic fever virus infection, equine infectious anemia virus infection, caprine arthritis virus infection, African swine fever virus infection, lentivirus infection, BK papovavirus infection, Murray Valley encephalitis virus infection, enterovirus infection, cytomegalovirus infection, pneumovirus infection, morbillivirus infection, and measles virus infection.

In some embodiments, the pregnant subject has or is at risk of having a medical condition that activates an immune response in the pregnant subject.

In some embodiments, the medical condition is pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dialated cardiomyopathy, serum sickness, chronic inflammatory demyelinating

polyneuropathy, systemic lupus, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune 5 dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune 10 lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, 15 scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

In some embodiments, the pregnant subject has a history of having had a previous fetus or neonate that had a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, an antibody associated with an immune disease is detected in a biological sample obtained from the pregnant subject.

20 In some embodiments, the biological sample is a blood or urine sample.

In some embodiments, the antibody binds human FcRn with a K_D of between 1 pM and 100 nM.

In some embodiments, the isolated antibody binds human FcRn with a K_D of less than or equal to that of antibody N026.

In some embodiments, the isolated antibody is a monoclonal antibody.

25 In some embodiments, the isolated antibody is IgG1 or variant thereof.

In some embodiments, the isolated antibody includes, comprises, consists of, or consists essentially of a λ light chain.

In some embodiments, the isolated antibody is a sialylated antibody.

30 In another aspect, the application features an isolated antibody comprising: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence X₁GTGSDVGSYNX₂VS (SEQ ID NO: 12), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence GDX₃X₄RPS (SEQ ID NO: 13), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence X₅SYX₆GSGIYV (SEQ ID NO: 14), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence

35 Z₁IGZ₂SGZ₃QTZ₄YADS (SEQ ID NO: 16), the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is a polar or hydrophobic amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino acid, X₅ is a polar 40 or hydrophobic amino acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is a

polar or hydrophobic amino acid, Z₃ is G, S, or A, Z₄ is a basic amino acid, Z₅ is a hydrophobic or basic amino acid, Z₆ is G, S, D, Q, or H, and Z₇ is S or T, for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the isolated antibody includes, comprises, consists of, or consists essentially of: (1) a light chain variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of, or consists essentially of a sequence having no more than two amino acid substitutions relative to the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 includes, comprises, consists of, or consists essentially of a sequence having no more than one amino acid substitution relative to the sequence of GDSERPS (SEQ ID NO: 2), the CDR L3 includes, comprises, consists of, or consists essentially of a sequence having no more than one amino acid substitution relative to the sequence of SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 includes, comprises, consists of, or consists essentially of a sequence having no more than one amino acid substitution relative to the sequence of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), or NYAMG (SEQ ID NO: 6), the CDR H2 includes, comprises, consists of, or consists essentially of a sequence having no more than two amino acid substitutions relative to the sequence of SIGASGSQTRYADS (SEQ ID NO: 8), SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS (SEQ ID NO: 41), SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), or TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 includes, comprises, consists of, or consists essentially of a sequence having no more than one amino acid substitution relative to the sequence of LAIGDSY (SEQ ID NO: 11), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody comprises the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TYAMG (SEQ ID NO: 4), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGSSGAQTRYADS (SEQ ID NO: 7) or TIGSSGAQTRYADS (SEQ ID NO: 41), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence DYAMG (SEQ ID NO: 5), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGSQTRYADS (SEQ ID NO: 8) or SIGASGSQTRYADS (SEQ ID NO: 42), and the CDR H3 of the isolated antibody

includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence NYAMG (SEQ ID NO: 6), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGAQTRYADS (SEQ ID NO: 9) or TIGASGAQTRYADS (SEQ ID NO: 43), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TYAMG (SEQ ID NO: 4), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGGQTRYADS (SEQ ID NO: 10) or TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TYAMG (SEQ ID NO: 4), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SIGASGSQTRYADS (SEQ ID NO: 8) or SIGASGSQTRYADS (SEQ ID NO: 42), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence $X_1GTGSDVGSYNX_2VS$ (SEQ ID NO: 12), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence GDX_3X_4RPS (SEQ ID NO: 13), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence $X_5SYX_6GSGIYV$ (SEQ ID NO: 14), the CDR H1 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence Z_1YAMG (SEQ ID NO: 15), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence $Z_7IGZ_2SGZ_3QTZ_4YADS$ (SEQ ID NO: 16), the CDR H3 of the isolated antibody includes, comprises, consists of, or consists

essentially of a sequence LAZ₅Z₆DSY (SEQ ID NO: 17), wherein X₁ is T, A, S, or I, X₂ is L or I, X₃ is S, N, or T, X₄ is Q, E, or N, X₅ is C, S, I, or Y, X₆ is A or V, Z₁ is E, T, D, or N, Z₂ is S or A, Z₃ is G, S, or A, Z₄ is K or R, Z₅ is I, L, or H, Z₆ is G, S, D, Q, or H, and Z₇ is S or T,

for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

5 In some embodiments, the CDR L1 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence GDSERPS (SEQ ID NO: 2), the CDR L3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 of the isolated antibody includes, comprises, 10 consists of, or consists essentially of a sequence Z₁YAMG (SEQ ID NO: 15), the CDR H2 of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence Z₇IGZ₂SGZ₃QTRYADS (SEQ ID NO: 18), and the CDR H3 of the isolated antibody includes, comprises, consists of, or consists essentially of the sequence LAIGDSY (SEQ ID NO: 11), and wherein Z₁ is T, D, or N, Z₂ is S or A, Z₃ is G, 15 S or A, and Z₇ is S or T, for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

20 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVS WYQQHPGKAPKLM IYGDSERPSGVSNRFSGSKS GNTASLTISGLQAED EADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPS VTLFPPSSEELQANKATLVCLI SDFYPPGAVTVAWKADSSPVKAGVETT PSKQSNNKYAASSYLSLTPEQWKSHKS YSCQVTHEGSTVEK TVAPTECS (SEQ ID NO: 19), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

25 In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTA VYYCARLAIGDSYWGQGT MVTVSSASTKGPSVFPLAPSSKSTSGG TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN 30 TKVDKKVEPKSCDKHTCPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20), for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

35 In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR FTISRDNSKNTLYLQMNSLRAEDTA VYYCARLAIGDSYWGQGT MVTVSSASTKGPSVFPLAPSSKSTSG 40 GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNNAKTKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21), for use in the treatment of a fetal and

5 neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR

10 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNNAKTKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
15 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

20 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNNAKTKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREP
25 QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

30 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
35 VDGVEVHNNAKTKPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS

5 GNTASLTISGLQAEDAEADYYCSSLYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

10 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSKSTSGG
TAALGCLVKDVFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
15 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence 20 of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAEADYYCSSLYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,

25 comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSKSTSG

GTAALGCLVKDVFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS

30 NTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

35 In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS

GNTASLTISGLQAEDAEADYYCSSLYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI

40 SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK

TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR

5 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAGQPREP
10 QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

15 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADEYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence

20 of

EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
25 YVDGVEVHNAKTPREEQYASTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKAGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes,

30 comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADEYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQVTHEGSTVEK
35 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
40 TAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN

TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24), for use in the treatment of a fetal and

5 neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the heavy chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of any one of SEQ ID NOs: 20-24, for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

10 In some embodiments, the light chain variable region of the isolated antibody includes, comprises, consists of, or consists essentially of a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of SEQ ID NO: 19, for use in the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes, 15 comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDAYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,
20 comprises, consists of, or consists essentially of the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSAQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
25 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
QQGVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes, 30 comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDAYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,
35 comprises, consists of, or consists essentially of the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
40 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP
REP

QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFYSKLTVDKSR
WQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes,

5 comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAYCSSLQAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
10 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,
comprises, consists of, or consists essentially of the sequence of
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
15 YVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFYSKLTVDKS
RWQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes,

20 comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAYCSSLQAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
25 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,
comprises, consists of, or consists essentially of the sequence of
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
30 YVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFYSKLTVDKS
RWQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In some embodiments, the light chain variable region of the isolated antibody includes,

35 comprises, consists of, or consists essentially of the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAYCSSLQAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
40 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region of the isolated antibody includes,
comprises, consists of, or consists essentially of the sequence of

EVQLLESGGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVWSNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNWKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
5 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24), for use in the treatment of a fetal and
neonatal alloimmune and/or autoimmune disorder.

In another aspect, the application features an isolated antibody comprising: (1) a light chain
10 variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region
comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of,
or consists essentially of a sequence VG₁Y₂N₃X₄, the CDR L2 includes, comprises, consists of, or
consists essentially of a sequence GDX₃X₄, the CDR L3 includes, comprises, consists of, or consists
essentially of a sequence YX₆GSGIY, the CDR H1 includes, comprises, consists of, or consists
essentially of a sequence Z₁YA, the CDR H2 includes, comprises, consists of, or consists essentially of a
15 sequence Z₈I₂Z₃S₄Z₅Q₆R, and the CDR H3 includes, comprises, consists of, or consists essentially of
a sequence LAZ₇, wherein X₁ is any amino acid, X₂ is L or I, X₃ is S, N, or T, X₄ is Q, E, or N, X₆ is A or V,
Z₁ is E, T, D, or N, Z₂ is any amino acid Z₃ is S or A, Z₄ is any amino acid, Z₅ is G, S, or A, Z₆ is any
amino acid, Z₇ is I, L, or H, and Z₈ is S or T.

20 In another aspect, the application features an isolated antibody comprising: (1) a light chain
variable region comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region
comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes, comprises, consists of,
or consists essentially of a sequence VG₁Y₂N₃X₄, the CDR L2 includes, comprises, consists of, or
consists essentially of a sequence GDX₃X₄, the CDR L3 includes, comprises, consists of, or consists
essentially of a sequence YX₆GSGIY, the CDR H1 includes, comprises, consists of, or consists
essentially of a sequence Z₁YA, the CDR H2 includes, comprises, consists of, or consists essentially of a
25 sequence Z₈I₂Z₃S₄Z₅Q₆R, and
the CDR H3 includes, comprises, consists of, or consists essentially of a sequence LAZ₇, wherein X₁ is
any amino acid, X₂ is a hydrophobic amino acid, X₃ is a polar amino acid, X₄ is a polar or acidic amino
30 acid, X₆ is a hydrophobic amino acid, Z₁ is a polar or acidic amino acid, Z₂ is any amino acid, Z₃ is a polar
or hydrophobic amino acid, Z₄ is any amino acid, Z₅ is G, S, or A, Z₅ is a hydrophobic or basic amino acid,
Z₆ is any amino acid, Z₇ is a hydrophobic or basic amino acid, and Z₈ is S or T.

35 In some embodiments, the antibody is for use in the treatment of a fetal and neonatal alloimmune
and/or autoimmune disorder. In some embodiments, the antibodies of the previous two aspects are for
use with any of the above methods.

In some embodiments, the isolated antibody is an anti-FcRn antibody. In some cases, the
antibody inhibits the binding of IgG to FcRn. In some embodiments, the isolated antibody does not bind
to E115 of FcRn (SEQ ID NO: 30). In some embodiments, the isolated antibody binds an epitope that
does not comprise E115 of FcRn (SEQ ID NO: 30).

The present application also features methods of decreasing pathogenic antibody transport across the placenta of a pregnant subject, increasing pathogenic antibody catabolism in a pregnant subject, and treating an antibody-mediated enhancement of viral disease in a fetus or a neonate by administering to a pregnant subject an isolated antibody that binds to human neonatal Fc receptor (FcRn). In some embodiments, the pathogenic antibody in the pregnant subject causes a fetal and neonatal alloimmune and/or autoimmune disorder in a fetus in the pregnant subject.

In some embodiments, the isolated antibody contains: (1) a light chain variable region that includes a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region that includes a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 has a sequence having no more than two amino acid substitutions relative to the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 has a sequence having no more than one amino acid substitution relative to the sequence of GDSERPS (SEQ ID NO: 2), the CDR L3 has a sequence having no more than one amino acid substitution relative to the sequence of SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 has a sequence having no more than one amino acid substitution relative to the sequence of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), or 5 NYAMG (SEQ ID NO: 6), the CDR H2 has a sequence having no more than two amino acid substitutions relative to the sequence of SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGSQTRYADS (SEQ ID NO: 8), SIGASGAQTRYADS (SEQ ID NO: 9), or SIGASGGQTRYADS (SEQ ID NO: 10), and the CDR H3 has a sequence having no more than one amino acid substitution relative to the sequence of LAIGDSY (SEQ ID NO: 11).

0 In some embodiments, the antibody binds human FcRn with a K_D of less than 200, 150, 100, 50, or 40 pM.

5 In some embodiments, the antibody binds human FcRn with a K_D that is less than or equal to that of an antibody having the light chain variable region and heavy chain variable region of N022, N023, N024, N026, or N027, and further having the same Fc region as that of the antibody to which it is being compared.

In other embodiments, the isolated antibody contains: (1) a light chain variable region that includes a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region that includes a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 has the sequence of X_1 GTGSDVGSYN X_2 VS (SEQ ID NO: 12), the CDR L2 has the sequence of GDX $_3$ X $_4$ RPS (SEQ ID NO: 13), the CDR L3 has the sequence of X $_5$ SYX $_6$ GSGIYV (SEQ ID NO: 14), the CDR H1 has the sequence of Z $_1$ YAMG (SEQ ID NO: 15), the CDR H2 has the sequence of SIGZ $_2$ SGZ $_3$ QTZ $_4$ YADS (SEQ ID NO: 45), and the CDR H3 has the sequence of LAZ $_5$ Z $_6$ DSY (SEQ ID NO: 17), wherein X $_1$ is a polar or hydrophobic amino acid, X $_2$ is a hydrophobic amino acid, X $_3$ is a polar amino acid, X $_4$ is a polar or acidic amino acid, X $_5$ is a polar or hydrophobic amino acid, X $_6$ is a hydrophobic amino acid, Z $_1$ is a polar or acidic amino acid, Z $_2$ is a polar or hydrophobic amino acid, Z $_3$ is G, S, or A, Z $_4$ is a basic amino acid, Z $_5$ is a hydrophobic or basic amino acid, and Z $_6$ is G, S, D, Q, or H, and wherein the antibody binds human FcRn with a K_D that is less than or equal to that of antibody having the light chain variable region and heavy chain variable region of N026 and further having the same Fc region as the antibody being compared. In some embodiments, X $_1$ is T, A, S, or I. In other embodiments, X $_2$ is L or I. In some embodiments, X $_3$ is S, N, or T. In still other embodiments, X $_4$ is Q, E, or N, X $_5$ is C, S, I, or Y. In some embodiments, X $_6$ is A or V, Z $_1$ is E, T, D, or N.

In further embodiments, Z₂ is S or A. In some embodiments, Z₄ is K or R. In yet other embodiments, Z₅ is I, L, or H.

In still other embodiments, the isolated antibody contains a light chain variable region that includes a CDR L1 having the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 having the sequence of GDSERPS (SEQ ID NO: 2), and a CDR L3 having the sequence of SSYAGSGIYV (SEQ ID NO: 3), and a heavy chain variable region that includes a CDR H1 having the sequence of Z₁YAMG (SEQ ID NO: 15), a CDR H2 having the sequence of SIGZ₂SGZ₃QTRYADS (SEQ ID NO: 44), and a CDR H3 having the sequence of LAIGDSY (SEQ ID NO: 11), wherein Z₁ is T, D, or N, Z₂ is S or A, and Z₃ is G, S or A.

10 In some embodiments, the isolated antibody contains a CDR L1 having the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 having the sequence of GDSERPS (SEQ ID NO: 2), a CDR L3 having the sequence of SSYAGSGIYV (SEQ ID NO: 3), a CDR H1 having the sequence of TYAMG (SEQ ID NO: 4), a CDR H2 having the sequence of SIGSSGAQTRYADS (SEQ ID NO: 7), and a CDR H3 having the sequence of LAIGDSY (SEQ ID NO: 11).

15 In some embodiments, the isolated antibody contains a CDR L1 having the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 having the sequence of GDSERPS (SEQ ID NO: 2), a CDR L3 having the sequence of SSYAGSGIYV (SEQ ID NO: 3), a CDR H1 having the sequence of DYAMG (SEQ ID NO: 5), a CDR H2 having the sequence of SIGASGSQTRYADS (SEQ ID NO: 8), and a CDR H3 having the sequence of LAIGDSY (SEQ ID NO: 11).

20 In some embodiments, the isolated antibody contains a CDR L1 having the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 having the sequence of GDSERPS (SEQ ID NO: 2), a CDR L3 having the sequence of SSYAGSGIYV (SEQ ID NO: 3), a CDR H1 having the sequence of NYAMG (SEQ ID NO: 6), a CDR H2 having the sequence of SIGASGAQTRYADS (SEQ ID NO: 9), and a CDR H3 having the sequence of LAIGDSY (SEQ ID NO: 11).

25 In other embodiments, the isolated antibody contains a CDR L1 having the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 having the sequence of GDSERPS (SEQ ID NO: 2), a CDR L3 having the sequence of SSYAGSGIYV (SEQ ID NO: 3), a CDR H1 having the sequence of TYAMG (SEQ ID NO: 4), a CDR H2 having the sequence of SIGASGGQTRYADS (SEQ ID NO: 10), and a CDR H3 having the sequence of LAIGDSY (SEQ ID NO: 11).

30 In yet other embodiments, the isolated antibody contains a CDR L1 having the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 having the sequence of GDSERPS (SEQ ID NO: 2), a CDR L3 having the sequence of SSYAGSGIYV (SEQ ID NO: 3), a CDR H1 having the sequence of TYAMG (SEQ ID NO: 4), a CDR H2 having the sequence of SIGASGSQTRYADS (SEQ ID NO: 8), and a CDR H3 having the sequence of LAIGDSY (SEQ ID NO: 11).

35 In some embodiments, the light chain variable region of the isolated antibody of the application has a sequence having at least 90% identity to the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTVLQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
40 TVAPTECS (SEQ ID NO: 19).

In some embodiments, the heavy chain variable region of the isolated antibody of the application has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
5 TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

10 In other embodiments, the heavy chain variable region of the isolated antibody of the application has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
15 NTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

20 In other embodiments, the heavy chain variable region of the isolated antibody of the application has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
25 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

In some embodiments, the heavy chain variable region of the isolated antibody of the application has a sequence having at least 90% identity to the sequence of

30 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
35 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

In other embodiments, the heavy chain variable region of the isolated antibody of the application has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
40

TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
 TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTEVTCVVVDVSHEDPEVKFNWY
 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
 VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR

5 WQQGVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

In some embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
 10 GNTASLTISGLQAEDeadYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
 SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSAQTRYADSVKGRF
 15 TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
 TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
 TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTEVTCVVVDVSHEDPEVKFNWY
 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
 VYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
 20 QQGVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

In other embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
 25 GNTASLTISGLQAEDeadYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
 SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
 30 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
 GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
 NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTEVTCVVVDVSHEDPEVKFNW
 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
 QVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
 35 WQQGVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

In other embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has a sequence having at least 90% identity to the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
 40 GNTASLTISGLQAEDeadYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI

SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR

5 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
10 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

In other embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has a sequence having at least 90% identity to the sequence of

QSALTQPASVGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
15 GNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR

20 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
25 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

In other embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has a sequence having at least 90% identity to the sequence of

QSALTQPASVGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
30 GNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90% identity to the sequence of

EVQLLESGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF

35 TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTWSNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
40 WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

In some embodiments, the heavy chain variable region of the isolated antibody of the application has a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of any one of SEQ ID NOs: 20-24. In other embodiments, the light chain variable region of the isolated antibody of the application has a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of SEQ ID NO: 19.

In some embodiments, the isolated antibody of the application further includes amino acid substitution N297A, relative to the sequence of any one of SEQ ID NOs: 20-24.

In other embodiments, the isolated antibody further includes amino acid substitutions D355E and L357M, relative to the sequence of any one of SEQ ID NOs: 20-24.

In other embodiments, the isolated antibody of the application further includes any one or more of the following amino acid substitutions: A23V, S30R, L80V, A84T, E85D, A93V, relative to the sequence of any one of SEQ ID NOs: 20-24 and Q38H, V58I, and G99D, relative to the sequence of SEQ ID NO: 19.

In yet other embodiment, the isolated antibody of the application does not contain a C-terminal lysine at residue 446, relative to the sequence of any one of SEQ ID NOs: 20-24.

In some embodiments, the antibody of any of the above aspects binds human FcRn with a K_D that is less than or equal to that of an antibody having the light chain variable region and heavy chain variable region of N022, N023, N024, N026, or N027 and also having the same Fc region as that of the antibody being compared. For example, in a particular K_D assay, the K_D of the antibody is less than 200, 150, 100, 50, or 40 pM.

The amino acid positions assigned to complementary determining regions (CDRs) and framework regions (FRs) of any isolated antibody described herein are defined according to EU index of Kabat (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)).

In some embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of QSLTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDADYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDLMISRTEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

In some embodiments, the isolated antibody contains a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of QSLTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKSGNTASLTISGLQAEDADYYCSSLAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of

SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
5 GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

10 In some embodiments, the isolated antibody contains a light chain variable region and a heavy
chain variable region, wherein the light chain variable region has the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
15 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
20 YVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

25 In some embodiments, the isolated antibody contains a light chain variable region and a heavy
chain variable region, wherein the light chain variable region has the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
30 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKS
35 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

35 In some embodiments, the isolated antibody contains a light chain variable region and a heavy
chain variable region, wherein the light chain variable region has the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI

SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWQQGTMVTSSASTKGPSVFPLAPSSKSTSGG
5 TAALGCLVKDYFPEPVTVWSNLGALTSGVHTFPALQSSGLYSLSSVTVPSQLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

10 In some embodiments of any of the above aspects, the isolated antibody of the application is a monoclonal antibody. In some embodiments, the isolated antibody is IgG1. In some embodiments, the isolated antibody includes a λ light chain. In some embodiments, the isolated antibody includes a kappa light chain. In some embodiments, the glycosylation site on the Fc region of the isolated antibody is sialylated (e.g., disialylated).

15 In some embodiments of any of the above aspects, the isolated antibody of the application is a humanized or fully human antibody.

In some embodiments, the isolated antibody binds to human FcRn with a K_D of 1-100, 5-150, 5-100, 5-75, 5-50, 10-50, or 10-40 pM.

20 In some embodiments, the isolated antibody of the application binds rodent, e.g., mouse or rat FcRn. In some embodiments, the isolated antibody of the application binds rodent, e.g., mouse or rat, FcRn with a K_D of less than 200, 150, 100, 50, or 40 pM.

25 The present application features novel antibodies to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful in methods of decreasing pathogenic antibody transport across the placenta of a pregnant subject, increasing pathogenic antibody catabolism in a pregnant subject, and treating an antibody-mediated enhancement of viral disease in a fetus or a neonate by administering to a pregnant subject an isolated antibody that binds to FcRn. In some 30 embodiments, the pathogenic antibody in the pregnant subject causes a fetal and neonatal alloimmune and/or autoimmune disorder in a fetus in the pregnant subject.

35 In one aspect, the application features an isolated antibody that binds to FcRn, wherein the antibody binds to: (a) at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25); and (b) at least one amino acid of the sequence of FKALGGKGPYTL (SEQ ID NO: 26), wherein the antibody inhibits the binding of IgG to human FcRn.

In another aspect, the application features an isolated antibody that binds to human FcRn, wherein the antibody binds to at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25), wherein the antibody binds to at least one of amino acid residues 5, 12, or 13 of SEQ ID NO: 25, and wherein the antibody inhibits the binding of IgG to human FcRn.

In another aspect, the application features an isolated antibody that binds to human FcRn, wherein the antibody binds to at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25), wherein the antibody does not bind to a peptide consisting of the sequence GEEFMNFDLKQGT (SEQ ID NO: 27) or one or more amino acids of the sequence of EEFMNFDL (SEQ ID NO: 28), and 5 wherein the antibody inhibits the binding of IgG to human FcRn.

In some embodiments, the antibody binds to at least one amino acid of the sequence of WGGDWPEAL (SEQ ID NO: 29).

In some embodiments, the antibody binds to at least amino acid residue 5 of SEQ ID NO: 25. In 10 some embodiments, the antibody binds to at least amino acid residue 12 of SEQ ID NO: 25. In some embodiments, the antibody binds to at least amino acid residue 13 of SEQ ID NO: 25.

In some embodiments, the antibody binds to at least one amino acid of the sequence of FKALGGKGPyTL (SEQ ID NO: 26). In some embodiments, the antibody at least two amino acids of the sequence of FKALGGKGPyTL (SEQ ID NO: 26).

In another aspect, the application features an isolated antibody that binds to human FcRn, 15 wherein the antibody binds at least one amino acid of the sequence of FKALGGKGPyTL (SEQ ID NO: 26), and wherein the antibody inhibits the binding of IgG to human FcRn. In some embodiments, the antibody binds to at least two amino acids of the sequence of FKALGGKGPyTL (SEQ ID NO: 26).

In some embodiments, the antibody further binds to at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25). In some embodiments, the antibody further binds to at least two 20 amino acids of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25).

In some embodiments, the antibody binds to at least one of amino acid residues 5, 12, or 13 of SEQ ID NO: 25. In some embodiments, the antibody binds to at least amino acid residue 5 of SEQ ID NO: 25. In some embodiments, the antibody binds to at least amino acid residue 12 of SEQ ID NO: 25. In some embodiments, the antibody binds to at least amino acid residue 13 of SEQ ID NO: 25.

25 In some embodiments, the antibody described herein binds human FcRn with a K_D of less than or equal to that of antibody N026.

In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is IgG1. In some embodiments, the antibody includes a λ light chain. In some embodiments, 30 the isolated antibody includes a kappa light chain. In some embodiments, the antibody is a sialylated (e.g., disialylated) antibody. In some embodiments, the antibody is a humanized or fully human antibody.

In another aspect, the application features a nucleic acid molecule encoding an isolated anti-FcRn antibody described herein.

In another aspect, the application features a vector including the nucleic acid molecule that encodes an isolated anti-FcRn antibody described herein.

35 In another aspect, the application features a host cell that expresses an isolated anti-FcRn antibody described herein, wherein the host cell includes a nucleic acid molecule that encodes the isolated anti-FcRn antibody or a vector that includes the nucleic acid molecule, wherein the nucleic acid molecule or vector is expressed in the host cell. In some embodiments, the host cell is a Chinese hamster ovary (CHO) cell.

In another aspect, the application features a pharmaceutical composition including an isolated anti-FcRn antibody described herein and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the antibody is in a therapeutically effective amount.

5 In another aspect, the application features a method of preparing an isolated anti-FcRn antibody described herein, wherein the method includes: a) providing a host cell including a nucleic acid molecule that encodes the isolated anti-FcRn antibody or a vector that includes the nucleic acid molecule, and b) expressing the nucleic acid molecule or vector in the host cell under conditions that allow for the formation of the antibody.

10 In some embodiments, the method further includes the step of recovering the antibody at a concentration of about 1-100, 1-50, 1-25, 2-50, 5-50, or 2-20 mg/ml.

In some embodiments, the host cell used in the method is a CHO cell.

15 In another aspect, the application features a method of increasing pathogenic antibody (e.g., an IgG antibody) catabolism in a subject. In another aspect, the application features a method of reducing autoantibodies in a subject. In yet another aspect, the application features a method of reducing an immune complex-based activation of an immune response in a subject. The methods include 20 administering to the subject an isolated antibody described herein or a pharmaceutical composition described herein.

In some embodiments, the immune response is an acute or chronic immune response in the subject.

25 In some embodiments, the acute immune response is activated by a medical condition selected from the group consisting of pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura (ITP), autoimmune haemolytic anaemia (AIHA), immune neutropenia, dilated cardiomyopathy, and serum sickness.

30 In some embodiments, the chronic immune response is activated by a medical condition selected from the group consisting of chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

35 In some embodiments, the subject has an autoimmune disease. The autoimmune disease may be alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcets disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, 40 polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary

agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

In another aspect, the application features a method of decreasing pathogenic antibody transport across the placenta of a pregnant subject. In another aspect, the application features a method of increasing pathogenic antibody catabolism in a pregnant subject. In yet another aspect, the application features a method of treating an antibody-mediated enhancement of viral disease in a fetus or a neonate. The methods include administering to the pregnant subject an isolated antibody described herein or a pharmaceutical composition described herein.

10 In some embodiments, the pathogenic antibody causes a fetal and neonatal alloimmune and/or autoimmune disorder in a fetus in the pregnant subject.

In some embodiments, the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia (FNAIT), hemolytic disease of the fetus and newborn (HDFN), alloimmune pan-thrombocytopenia, congenital heart 15 block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.

In some embodiments, the pathogenic antibody is an IgG antibody.

20 In some embodiments, the viral disease is caused by a virus selected from the group consisting of an alpha virus infection, flavivirus infection, Zika virus infection, Chikungunya virus infection, Ross River virus infection, severe acute respiratory syndrome coronavirus infection, Middle East respiratory syndrome, avian influenza infection, influenza virus infection, human respiratory syncytial virus infection, Ebola virus infection, yellow fever virus infection, dengue virus infection, human immunodeficiency virus 25 infection, respiratory syncytial virus infection, Hantavirus infection, Getah virus infection, Sindbis virus infection, Bunyamwera virus infection, West Nile virus infection, Japanese encephalitis virus B infection, rabbitpox virus infection, lactate dehydrogenase elevating virus infection, reovirus infection, rabies virus infection, foot-and-mouth disease virus infection, porcine reproductive and respiratory syndrome virus infection, simian hemorrhagic fever virus infection, equine infectious anemia virus infection, caprine 30 arthritis virus infection, African swine fever virus infection, lentivirus infection, BK papovavirus infection, Murray Valley encephalitis virus infection, enterovirus infection, cytomegalovirus infection, pneumovirus infection, morbillivirus infection, and measles virus infection.

In some embodiments, the pregnant subject has or is at risk of having a medical condition that activates an immune response in the pregnant subject. In some embodiments, the medical condition is 35 pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dialated cardiomyopathy, serum sickness, chronic inflammatory demyelinating polyneuropathy, systemic lupus, 40 reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, antineutrophil cytoplasmic antibody

(ANCA)-associated vasculitis, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, 5 limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious 10 anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

15 In some embodiments, the pregnant subject has a history of having had a previous fetus or neonate that had a fetal and neonatal alloimmune and/or autoimmune disorder.

In some embodiments, a pathogenic antibody associated with an immune disease is detected in a biological sample (e.g., a blood or urine sample) obtained from the pregnant subject.

20 In some embodiments, the isolated anti-FcRn antibody of the application binds rodent, e.g., mouse or rat FcRn. In some embodiments, the isolated anti-FcRn antibody of the application binds rodent, e.g., mouse or rat, FcRn with a K_D of less than 200, 150, 100, 50, or 40 pM.

Definitions

25 The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit FcRn antigen-binding activity.

30 "Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')₂, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies.

As used herein, the term "isolated antibody" refers to an antibody which has been separated and/or recovered from a component of its manufacturing host cell environment. Contaminant components of its manufacturing host cell environment are materials which would interfere with research, diagnostic, or therapeutic uses of the antibody. Contaminant components may include enzymes, 35 hormones, and other proteinaceous or nonproteinaceous solutes. In some embodiments, an antibody is purified (1) to greater than 95% by weight of antibody as determined by, for example, the Lowry method, and in some embodiments, to greater than 99% by weight; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of, for example, a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or non-reducing conditions using, for 40 example, Coomassie blue or silver stain. An isolated antibody includes the antibody *in situ* within

recombinant cells. Ordinarily, however, an isolated antibody will be prepared by at least one purification step. A pharmaceutical preparation of an isolated antibody typically has less than 250 ppm (e.g., less than 200 ppm, 150 ppm, 100 ppm) of host cell proteins (HCP) as determined by an ELISA based HCP assay performed as recommended by an FDA “Guidance for Industry” document.

5 As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies in the population have the same primary sequence except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and directed against a single antigenic site (i.e., an epitope on human FcRn). In contrast to polyclonal antibody preparations which typically include different 10 antibodies directed against different epitopes, each monoclonal antibody is directed against a single epitope on the antigen. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogenous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.

15 As used herein, the terms “variable region” and “variable domain” refer to the portions of the light and heavy chains of an antibody that include amino acid sequences of complementary determining regions (CDRs, e.g., CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3) and framework regions (FRs). According to the methods used in this disclosure, the amino acid positions assigned to CDRs and 20 FRs are defined according to Kabat (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a CDR (defined further herein) or FR (defined further herein) of the 25 variable region. For example, a heavy chain variable region may include a single inserted residue (i.e., residue 52a according to Kabat) after residue 52 of CDR H2 and inserted residues (i.e., residues 82a, 82b, 82c, etc. according to Kabat) after residue 82 of heavy chain FR. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.

30 As used herein, the terms “complementary determining regions” and “CDRs” refer to the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops. A CDR is also known as a hypervariable region. The light chain and heavy chain variable regions each has three CDRs. The light chain variable region contains CDR L1, CDR L2, and CDR L3. The heavy chain variable region contains CDR H1, CDR H2, and CDR H3. Each CDR may include amino acid residues from a complementarity determining region as defined by Kabat (i.e. about residues 24-34 (CDR L1), 50-56 (CDR L2) and 89-97 (CDR L3) in the light chain variable region and about residues 31-35 (CDR H1), 50-65 (CDR H2) and 95-102 (CDR H3) in the heavy chain variable region.

35 As used herein, the term “FcRn” refers to a neonatal Fc receptor that binds to the Fc region of an IgG antibody, e.g., an IgG1 antibody. An exemplary FcRn is human FcRn having UniProt ID No. P55899. Human FcRn is believed to be responsible for maintaining the half-life of IgG by binding and trafficking 40 constitutively internalized IgG back to the cell surface for the recycling of IgG.

As used herein, the terms “affinity” and “binding affinity” refer to the strength of the binding interaction between two molecules. Generally, binding affinity refers to the strength of the sum total of

non-covalent interactions between a single binding site of a molecule and its binding partner, such as an isolated antibody and its target (e.g., an isolated anti-FcRn antibody and a human FcRn). Unless indicated otherwise, binding affinity refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair. The binding affinity between two molecules is commonly described 5 by the dissociation constant (K_D) or the affinity constant (K_A). Two molecules that have low binding affinity for each other generally bind slowly, tend to dissociate easily, and exhibit a large K_D . Two molecules that have high affinity for each other generally bind readily, tend to remain bound longer, and exhibit a small K_D . One method for determining the K_D of an antibody to human FcRn is described in Example 2 ("the SPR (Surface Plasmon Resonance) method"). Using this method the K_D of N022, N023, 10 N024, N026, and N027 was 31, 31.4, 35.5, 36.5, and 19.3 pM, respectively.

As used herein, the term "inhibit IgG binding to FcRn" refers to the ability of an anti-FcRn antibody to block or inhibit the binding of IgG (e.g., IgG1) to human FcRn. In some embodiments, an anti-FcRn antibody binds FcRn, for example, at the site on human FcRn to which IgG binds. Thus, the anti-FcRn antibody is able to inhibit the binding of IgG (e.g., a subject's autoantibodies) to FcRn. In some 15 embodiments, the molecule (e.g., an anti-FcRn antibody) substantially or completely inhibits binding to IgG. In some embodiments, the binding of IgG is reduced by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even 100%.

As used herein, the term "inhibit pathogenic antibody binding to FcRn" refers to the ability of an anti-FcRn antibody to block or inhibit the binding of a pathogenic antibody (e.g., pathogenic IgG antibody) 20 to human FcRn. In some embodiments, an anti-FcRn antibody binds FcRn, for example, at the site on human FcRn to which the pathogenic antibody binds. Thus, the anti-FcRn antibody is able to inhibit the binding of pathogenic antibodies (e.g., pathogenic IgG antibodies) to FcRn. In some embodiments, the molecule (e.g., an anti-FcRn antibody) substantially or completely inhibits binding to pathogenic 25 antibodies. In some embodiments, the binding of pathogenic antibodies to FcRn is reduced by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even 100%.

As used herein, the term "hydrophobic amino acid" refers to an amino acid having relatively low-water solubility. Hydrophobic amino acids are glycine, leucine, isoleucine, alanine, phenylalanine, methionine, tryptophan, valine, and proline. Particularly preferred hydrophobic amino acids in the present disclosure are alanine, leucine, isoleucine, and valine.

As used herein, the term "polar amino acid" refers to an amino acid having a chemical polarity in 30 its side chain induced by atoms with different electronegativity. The polarity of a polar amino acid is dependent on the electronegativity between atoms in the side chain of the amino acid and the asymmetry of the structure of the side chain. Polar amino acids are serine, threonine, cysteine, histidine, methionine, tyrosine, tryptophan, asparagine, and glutamine. Particularly preferred polar amino acids in the present 35 disclosure are serine, threonine, asparagine, glutamine, cysteine, and tyrosine.

As used herein, the term "acidic amino acid" refers to an amino acid whose side chain contains a carboxylic acid group having a pKa between 3.5 and 4.5. Acidic amino acids are aspartic acid and glutamic acid.

As used herein, the term "basic amino acid" refers to an amino acid whose side chain contains an 40 amino group having a pKa between 9.5 and 13. Basic amino acids are histidine, lysine, and arginine.

As used herein, the term “percent (%) identity” refers to the percentage of amino acid (or nucleic acid) residues of a candidate sequence, e.g., an anti-FcRn antibody, that are identical to the amino acid (or nucleic acid) residues of a reference sequence, e.g., a wild-type anti-FcRn antibody, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity (i.e., gaps can be 5 introduced in one or both of the candidate and reference sequences for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). Alignment for purposes of determining percent identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, 10 including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. In some embodiments, the percent amino acid (or nucleic acid) sequence identity of a given candidate sequence to, with, or against a given reference sequence (which can alternatively be phrased as a given candidate sequence that has or includes a certain percent amino acid (or nucleic acid) sequence identity to, with, or against a given reference sequence) is calculated as follows:

15
$$100 \times (\text{fraction of A/B})$$

where A is the number of amino acid (or nucleic acid) residues scored as identical in the alignment of the candidate sequence and the reference sequence, and where B is the total number of amino acid (or nucleic acid) residues in the reference sequence. In some embodiments where the length of the candidate sequence does not equal to the length of the reference sequence, the percent amino acid (or 20 nucleic acid) sequence identity of the candidate sequence to the reference sequence would not equal to the percent amino acid (or nucleic acid) sequence identity of the reference sequence to the candidate sequence.

In particular embodiments, a reference sequence aligned for comparison with a candidate sequence may show that the candidate sequence exhibits from 50% to 100% identity across the full 25 length of the candidate sequence or a selected portion of contiguous amino acid (or nucleic acid) residues of the candidate sequence. The length of the candidate sequence aligned for comparison purpose is at least 30%, e.g., at least 40%, e.g., at least 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence. When a position in the candidate sequence is occupied by the same amino acid (or nucleic acid) residue as the corresponding position in the reference sequence, then the 30 molecules are identical at that position. A position may be altered by a substitution, deletion, or insertion. A substitution, deletion, or insertion may comprise a certain number of amino acids, (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more). When describing a substitution, deletion, or insertion of no more than n amino acids, this is meant that the substitution, deletion, or insertion comprises, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, ... or n amino acids. The number of substitutions, deletions, or 35 insertions can comprise a percent of the total sequence (e.g., 1%, 5%, 10%, 15%, 20%, or more) where the number of substitutions, deletions, or insertions alters 5%, 10%, 15%, 20% or more, of the amino acids in the total sequence. As used herein, the term “fetal and neonatal alloimmune and/or autoimmune disorder” refers to an immune disorder in a fetus and/or neonate that is caused by the transplacental transfer of maternal antibodies (e.g., pathogenic maternal antibodies) directed against fetal and/or 40 neonate antigens. For example, a pregnant subject’s antibodies (e.g., pathogenic antibodies) may react

against antigens in the fetus (e.g., antigens the fetus inherited from the fetus' father). Examples of fetal and neonatal alloimmune and/or autoimmune disorders are provided herein.

As used herein, the term "pathogenic antibody" refers to an antibody that causes one or more immune diseases or disorders in a subject (e.g., a pregnant subject), a fetus in a pregnant subject, and/or a neonate. In some embodiments, pathogenic antibodies are autoantibodies produced in a subject (e.g., a pregnant subject) against one or more of the subject's own proteins, thus causing autoimmune diseases or disorders in the subject. In some embodiments, pathogenic antibodies in a pregnant subject may transfer through the placenta to the fetus and react against antigens from the fetus (e.g., antigens that the fetus inherited from the fetus' father), thus causing, e.g., fetal and neonatal alloimmune and/or autoimmune disorders.

As used herein, the term "antibody-mediated enhancement of viral disease" refers to a viral disease in which antibodies can facilitate viral entry into host cells, thus leading to increased or enhanced infectivity in the cells. In some embodiments, an antibody may bind to a viral surface protein and the antibody/virus complex may bind to an FcRn receptor on a cell surface through interaction between the antibody and the receptor. Subsequently, the antibody/virus complex may get internalized into the cell.

As used herein, the term "host cell" refers to a vehicle that includes the necessary cellular components, e.g., organelles, needed to express proteins from their corresponding nucleic acids. The nucleic acids are typically included in nucleic acid vectors that can be introduced into the host cell by conventional techniques known in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, etc.). A host cell may be a prokaryotic cell, e.g., a bacterial cell, or a eukaryotic cell, e.g., a mammalian cell (e.g., a CHO cell). As described herein, a host cell is used to express one or more polypeptides encoding anti-FcRn antibodies.

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid molecule to which it has been linked. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a phage vector. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "recombinant vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.

As used herein, the term "subject" refers to a mammal, e.g., preferably a human. Mammals include, but are not limited to, humans and domestic and farm animals, such as monkeys (e.g., a cynomolgus monkey), mice, dogs, cats, horses, and cows, etc.

As used herein, the term "pharmaceutical composition" refers to a medicinal or pharmaceutical formulation that contains an active ingredient as well as one or more excipients and diluents to enable the active ingredient suitable for the method of administration. The pharmaceutical composition includes

pharmaceutically acceptable components that are compatible with the anti-FcRn antibody. The pharmaceutical composition may be in aqueous form for intravenous or subcutaneous administration or in tablet or capsule form for oral administration.

As used herein, the term "pharmaceutically acceptable carrier" refers to an excipient or diluent in a pharmaceutical composition. The pharmaceutically acceptable carrier must be compatible with the other ingredients of the formulation and not deleterious to the recipient. The pharmaceutically acceptable carrier must provide adequate pharmaceutical stability to the Fc construct. The nature of the carrier differs with the mode of administration. For example, for intravenous administration, an aqueous solution carrier is generally used; for oral administration, a solid carrier is preferred.

As used herein, the term "therapeutically effective amount" refers to an amount, e.g., pharmaceutical dose, effective in inducing a desired biological effect in a subject or patient or in treating a patient having a condition or disorder described herein. It is also to be understood herein that a "therapeutically effective amount" may be interpreted as an amount giving a desired therapeutic effect, either taken in one dose or in any dosage or route, taken alone or in combination with other therapeutic agents.

As used herein, the term "no more than" refers to an amount that is less than equal to. This may be an amount in integers. For example, no more than two substitutions can refer to 0, 1, or 2 substitutions.

As used herein, the terms "treatment" or "treating" refer to reducing, decreasing, decreasing the risk of, or decreasing the side effects of a particular disease or condition. Reducing, decreasing, decreasing the risk of, or decreasing the side effects of are relative to a subject who did not receive treatment, e.g, a control, a baseline, or a known control level or measurement.

DESCRIPTION OF THE DRAWINGS

FIG. 1 shows two graphs and a table that show IgG competitive binding of antibodies N022- N024, N026, and N027 to human or cynomolgus monkey FcRn at pH 6.0.

FIG. 2 shows graphs that show the effects of antibodies N023, N024, N026, and N027 on IgG catabolism in transgenic mice.

FIG. 3 shows graphs that show the dose-dependent effects of antibody N027 on IgG levels and target occupancy in transgenic mice.

FIGS. 4A-4C show graphs that show the selective induction of IgG catabolism and target occupancy in cynomolgus monkeys following administration of different doses of antibody N027.

FIG. 5 shows a graph that shows the biodistribution of N027 in transgenic mice.

FIG. 6 shows an experimental timeline and a graph that shows the efficacy of N027 in a mouse collagen antibody-induced arthritis model in transgenic mice.

FIG. 7 shows an experimental timeline and two graphs that show the efficacy of N027 in a mouse chronic idiopathic thrombocytopenia purpura (ITP) model in transgenic mice.

FIGS. 8A-8C show graphs that show the dose-dependent FcRn occupancy achieved with N027 in aortic endothelial cells, venous endothelial cells, and placental trophoblast, respectively.

FIGS. 9A-9C show graphs that show 100% FcRn occupancy by N027 results in increased intracellular IgG accumulation in aortic endothelial cells, venous endothelial cells, and placental trophoblast, respectively.

5 **FIG. 10** shows a graph that shows the amount of time it takes to achieve 100% FcRn occupancy by N027.

FIGS. 11A and **11B** show graphs that show N027 treatment does not alter FcRn turnover rates in human endothelial and villous trophoblast cells, respectively.

FIGS. 12A and **12B** show images of FcRn localized in endosomes in human endothelial and villous trophoblast cells.

10 **FIGS. 13A** and **13B** show graphs that show the effect of N027 treatment on dynamics of IgG trafficking in human endothelial cells and human placental trophoblasts, respectively.

FIGS. 13C and **13D** show images that show N027 increases intracellular IgG and co-localization of IgG with lysosomes (lysosomal markers: Lamp-1 and Dextran).

15 **FIG. 14** shows images of a comparison of the N027 Fab binding site on FcRn with Fc and albumin binding sites. Fab and Fc binding sites overlap with each other but are distinct from the albumin binding site.

FIG. 15 shows images of the epitope on the N027 Fab surface (left) and paratope on the FcRn surface (right).

FIG. 16 shows the N027 Fab:FcRn epitope and paratope mapped to sequences.

20 **FIG. 17** is a graph that shows transplacental transfer of antipyrine over four hours of perfusion (n=14). The data represent antipyrine concentrations as mean \pm standard deviation (SD) in the fetal (squares) and maternal (circles) circulation after maternal administration of 100 μ g/ml antipyrine at t=0.

25 **FIG. 18** is a graph that shows transplacental transfer of N027 over four hours of perfusion. The data represent N027 concentrations as mean \pm SD in the fetal and maternal circulation after maternal administration of the indicated concentration of N027 at t=0.

FIG. 19 is a graph showing maternal IgG concentrations after treatment with N027 during gestation.

FIG. 20 is a graph showing fetal IgG levels after treatment of mothers with N027 during gestation.

30

DETAILED DESCRIPTION

The present disclosure features isolated antibodies that bind to human neonatal Fc receptor (FcRn) with high affinity. The present disclosure features anti-FcRn antibodies, methods and compositions for preparing anti-FcRn antibodies, and methods for blocking FcRn activity, reducing immune complex-based activation of an immune response, and treating immunological diseases.

35 Furthermore, anti-FcRn antibodies can be used to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

I. Anti-FcRn antibodies

In general, the disclosure features isolated antibodies that bind to the human FcRn. An anti-FcRn antibody refers to an antibody that can bind to human FcRn and inhibit IgG (e.g., IgG autoantibodies or pathogenic antibodies) binding to FcRn. In some embodiments, the antibody is a monoclonal antibody. In other embodiments, the antibody is a polyclonal antibody. In some embodiment, the antibody is IgG1. In some embodiment, the antibody includes a λ light chain. In some embodiment, the antibody is a sialylated antibody. In some embodiments, the antibody is selected from the group consisting of a chimeric antibody, an affinity matured antibody, a humanized antibody, and a human antibody. In certain embodiments, the antibody is an antibody fragment, e.g., a Fab, Fab', Fab'-SH, F(ab')₂, or scFv.

In some embodiments, the antibody is a chimeric antibody. For example, an antibody contains antigen binding sequences from a non-human donor grafted to a heterologous non-human, human, or humanized sequence (e.g., framework and/or constant domain sequences). In one embodiment, the non-human donor is a mouse. In another embodiment, an antigen binding sequence is synthetic, e.g., obtained by mutagenesis (e.g., phage display screening, etc.). In a further embodiment, a chimeric antibody has non-human (e.g., mouse) variable regions and human constant regions. In one example, a mouse light chain variable region is fused to a human κ light chain. In another example, a mouse heavy chain variable region is fused to a human IgG1 constant region.

In some embodiments, when describing the CDR sequences of an antibody, the antibody is defined as including a set of 6 CDR sequences. Including a set of CDR sequences describes an antibody that consists of, comprises, or consists essentially of these CDR sequences.

In one aspect, the disclosure features an isolated antibody that binds to human neonatal Fc receptor (FcRn), the isolated antibody including: (1) a light chain variable region including a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region comprising a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 includes the sequence SDVGSYNL(SEQ ID NO: 47) or VG_YNL(SEQ ID NO: 34), wherein the “_” can be any amino acid, the CDR L2 includes the sequence GDSE (SEQ ID NO: 35), the CDR L3 includes the sequence YAGSGIY (SEQ ID NO: 36), the CDR H1 includes the sequence TYA(SEQ ID NO: 37), the CDR H2 includes the sequence SIGASGSQTR (SEQ ID NO: 38) or SI_AS_SQ_R (SEQ ID NO: 39), wherein the “_” can be any amino acid, and the CDR H3 includes the sequence LAI (SEQ ID NO: 40), and, optionally, wherein (a) the CDR L1 has a deletion or has more than two amino acid substitutions relative to the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), (b) the CDR L2 has a deletion or has more than one amino acid substitution relative to the sequence of GDSERPS (SEQ ID NO: 2), (c) the CDR L3 has a deletion or has more than one amino acid substitution relative to the sequence of SSYAGSGIYV (SEQ ID NO: 3), (d) the CDR H1 has a deletion or has more than one amino acid substitution relative to each of the sequences of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), and NYAMG (SEQ ID NO: 6), (e) the CDR H2 has a deletion or has more than two amino acid substitutions relative to each of the sequences of SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGSQTRYADS (SEQ ID NO: 8), SIGASGAQTRYADS (SEQ ID NO: 9), and SIGASGGQTRYADS (SEQ ID NO: 10), or (f) the CDR H3 has a deletion or has more than one amino acid substitutions relative

to the sequence of LAIGDSY (SEQ ID NO: 11). In some embodiments, the isolated antibody comprises the amino acid sequence KSG at Kabat positions 66-68.

In another aspect, the disclosure features an isolated antibody that binds to human FcRn, wherein the antibody binds to an epitope on FcRn comprising at least one, two, three, four, five, six, 5 seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty amino acids selected from the group consisting of K80, A81, L82, G83, G84, K85, G86, P87, Y88, L112, N113, E115, G129, D130, W131, P132, E133, L135, A136, and Q139 of SEQ ID NO: 30, which corresponds to amino acids K103, A104, L105, G106, G107, K108, G109, P110, Y111, L135, 10 N136, E138, G152, D153, W154, P155, E156, L158, A159, Q162, respectively, of wildtype FcRn. In some embodiments, the epitope on FcRn does not comprise E115, which corresponds to amino acid 15 E138 of wildtype FcRn.

In another aspect, the disclosure features an isolated antibody that binds to an epitope on β 2-microglobulin comprising at least one amino acid selected from the group consisting of I21, Q22, P52, and V105.

15 In another aspect, the disclosure features an isolated antibody that binds to FcRn, wherein the antibody binds to: (a) at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25); and (b) at least one amino acid of the sequence of FKALGGKGPYTL (SEQ ID NO: 26), wherein the antibody inhibits the binding of IgG to human FcRn.

20 The disclosure also features an isolated antibody that binds to human FcRn, wherein the antibody binds to at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25), wherein the antibody binds to at least one of amino acid residues 5, 12, or 13 of SEQ ID NO: 25, and wherein the antibody inhibits the binding of IgG to human FcRn.

25 The disclosure also features an isolated antibody that binds to human FcRn, wherein the antibody binds to at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25), wherein the antibody does not bind to a peptide consisting of the sequence EFMNFDLKQGT (SEQ ID NO: 27) or the sequence of EEFMNFDL (SEQ ID NO: 28), and wherein the antibody inhibits the binding of IgG to human FcRn.

30 In some embodiments, the anti-FcRn antibody described herein binds to at least one amino acid of the sequence of WGGDWPEAL (SEQ ID NO: 29). In some embodiments, the anti-FcRn antibody binds to at least amino acid residue 5 of SEQ ID NO: 25. In some embodiments, the anti-FcRn antibody binds to at least amino acid residue 12 of SEQ ID NO: 25. In some embodiments, the anti-FcRn antibody binds at least amino acid residue 13 of SEQ ID NO: 25.

35 In some embodiments, the anti-FcRn antibody binds to at least one amino acid of the sequence of FKALGGKGPYTL (SEQ ID NO: 26). The anti-FcRn antibody may also bind to at least two amino acids of the sequence of FKALGGKGPYTL (SEQ ID NO: 26).

In another aspect, the disclosure also features an isolated antibody that binds to human FcRn, wherein the antibody binds to at least one amino acid of the sequence of FKALGGKGPYTL (SEQ ID NO: 26), and wherein the antibody inhibits the binding of IgG to human FcRn.

40 In some embodiments of this aspect, the anti-FcRn antibody binds to at least two amino acids of the sequence of FKALGGKGPYTL (SEQ ID NO: 26). In some embodiments, the anti-FcRn antibody

further binds to at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25). In some embodiments, the anti-FcRn antibody further binds to at least two amino acids of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25). In some embodiments, the anti-FcRn antibody binds to at least one of amino acid residues 5, 12, or 13 of SEQ ID NO: 25. In some embodiments, the anti-FcRn antibody binds to at least amino acid residue 5 of SEQ ID NO: 25. In some embodiments, the anti-FcRn antibody binds to at least amino acid residue 12 of SEQ ID NO: 25. In some embodiments, the anti-FcRn antibody binds to at least amino acid residue 13 of SEQ ID NO: 25.

In another aspect, the disclosure features an isolated antibody capable of binding to human FcRn. The isolated antibody contains: (1) a light chain variable region that includes a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain variable region that includes a CDR H1, a CDR H2, and a CDR H3, wherein the CDR L1 has a sequence having at least 92% identity to the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), the CDR L2 has a sequence having at least 85% identity to the sequence of GDSERPS (SEQ ID NO: 2), the CDR L3 has a sequence having at least 90% identity to the sequence of SSYAGSGIYV (SEQ ID NO: 3), the CDR H1 has a sequence having at least 80% identity to the sequence of TYAMG (SEQ ID NO: 4), DYAMG (SEQ ID NO: 5), or NYAMG (SEQ ID NO: 6), the CDR H2 has a sequence having at least 92% identity to the sequence of SIGSSGAQTRYADS (SEQ ID NO: 7), SIGASGSQTRYADS (SEQ ID NO: 8), SIGASGAQTRYADS (SEQ ID NO: 9), SIGASGGQTRYADS (SEQ ID NO: 10), TIGSSGAQTRYADS (SEQ ID NO: 41), SIGASGSQTRYADS (SEQ ID NO: 42), TIGASGAQTRYADS (SEQ ID NO: 43), or TIGASGGQTRYADS (SEQ ID NO: 46), and the CDR H3 has a sequence having at least 85% identity to the sequence of LAIGDSY (SEQ ID NO: 11). In some embodiments, the antibody binds human FcRn with a K_D of less than 200, 150, 100, 50, or 40 pM. In some embodiments, the antibody binds human FcRn with a K_D that is less than or equal (e.g., less than) to that of an antibody having the light chain variable region and heavy chain variable region of N022, N023, N024, N026, or N027, and further having the same Fc region as the antibody being compared.

In some embodiments, an isolated antibody has a CDR L1 that comprises, consists of, consists essentially of, or has the sequence of X_1 GTGSDVGSYN X_2 VS (SEQ ID NO: 12), a CDR L2 that comprises, consists of, consists essentially of, or has the sequence of GDX $_3$ X $_4$ RPS (SEQ ID NO: 13), a CDR L3 that comprises, consists of, consists essentially of, or has the sequence of X $_5$ SYX $_6$ GSGIYV (SEQ ID NO: 14), a CDR H1 that comprises, consists of, consists essentially of, or has the sequence of Z $_1$ YAMG (SEQ ID NO: 15), a CDR H2 that comprises, consists of, consists essentially of, or has the sequence of Z $_7$ IGZ $_2$ SGZ $_3$ QTZ $_4$ YADS (SEQ ID NO: 16), and a CDR H3 that comprises, consists of, consists essentially of, or has the sequence of LAZ $_5$ Z $_6$ DSY (SEQ ID NO: 17), where X_1 is a polar or hydrophobic amino acid (e.g., preferably T, A, S, or I), X_2 is a hydrophobic amino acid (e.g., preferably L or I), X_3 is a polar amino acid (e.g., preferably S, N, or T), X_4 is a polar or acidic amino acid (e.g., preferably Q, E, or N), X_5 is a polar or hydrophobic amino acid (e.g., preferably C, S, I, or Y), X_6 is a hydrophobic amino acid (e.g., preferably A or V), Z_1 is a polar or acidic amino acid (e.g., preferably E, T, D, or N), Z_2 is a polar or hydrophobic amino acid (e.g., preferably S or A), Z_3 is G, S, or A, Z_4 is a basic amino acid (e.g., preferably K or R), Z_5 is a hydrophobic or basic amino acid (e.g., preferably I, L, or H), Z_6 is G, S, D, Q, or H, and Z_7 is S or T, and where the antibody binds human FcRn with a K_D of less than 200, 150, 100, 50, or 40 pM.

In other embodiments, an isolated antibody has a CDR L1 that has the sequence of TGTGSDVGSYNLVS (SEQ ID NO: 1), a CDR L2 that has the sequence of GDSERPS (SEQ ID NO: 2), a CDR L3 that has the sequence of SSYAGSGIYV (SEQ ID NO: 3), a CDR H1 that has the sequence of Z₁YAMG (SEQ ID NO: 15), a CDR H2 that has the sequence of Z₇IGZ₂SGZ₃QTRYADS (SEQ ID NO: 18),

5 and a CDR H3 that has the sequence of LAIGDSY (SEQ ID NO: 11), where Z₁ is T, D, or N, Z₂ is S or A, Z₃ is G, S or A, and Z₇ is S or T.

Table 1 shows the amino acid sequences of the light and heavy chain complementary determining regions (CDRs) of some exemplary anti-FcRn antibodies.

10

Table 1

Anti-FcRn antibody	CDR L1	CDR L2	CDR L3	CDR H1	CDR H2	CDR H3
N022	TGTGSDVGSYNLVS (SEQ ID NO: 1)	GDSERPS (SEQ ID NO: 2)	SSYAGSGIYV (SEQ ID NO: 3)	TYAMG (SEQ ID NO: 4)	SIGSSGAQTRYADS (SEQ ID NO: 7)	LAIGDSY (SEQ ID NO: 11)
N023	TGTGSDVGSYNLVS (SEQ ID NO: 1)	GDSERPS (SEQ ID NO: 2)	SSYAGSGIYV (SEQ ID NO: 3)	DYAMG (SEQ ID NO: 5)	SIGASGSQTRYADS (SEQ ID NO: 8)	LAIGDSY (SEQ ID NO: 11)
N024	TGTGSDVGSYNLVS (SEQ ID NO: 1)	GDSERPS (SEQ ID NO: 2)	SSYAGSGIYV (SEQ ID NO: 3)	NYAMG (SEQ ID NO: 6)	SIGASGAQTRYADS (SEQ ID NO: 9)	LAIGDSY (SEQ ID NO: 11)
N026	TGTGSDVGSYNLVS (SEQ ID NO: 1)	GDSERPS (SEQ ID NO: 2)	SSYAGSGIYV (SEQ ID NO: 3)	TYAMG (SEQ ID NO: 4)	SIGASGGQTRYADS (SEQ ID NO: 10)	LAIGDSY (SEQ ID NO: 11)
N027	TGTGSDVGSYNLVS (SEQ ID NO: 1)	GDSERPS (SEQ ID NO: 2)	SSYAGSGIYV (SEQ ID NO: 3)	TYAMG (SEQ ID NO: 4)	SIGASGSQTRYADS (SEQ ID NO: 8)	LAIGDSY (SEQ ID NO: 11)

Table 2 shows the SEQ ID NOs of the light and heavy chain variable regions of these exemplary anti-FcRn antibodies.

15

Table 2

Anti-FcRn antibody	Light Chain Variable Region	Heavy Chain Variable Region
N022	SEQ ID NO: 19	SEQ ID NO: 20
N023		SEQ ID NO: 21
N024		SEQ ID NO: 22
N026		SEQ ID NO: 23
N027		SEQ ID NO: 24

In some embodiments, the light chain variable region of an isolated antibody has a sequence having at least 90% identity to the sequence of
 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
 20 GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI

SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSQCVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19).

In some embodiments, the heavy chain variable region of an isolated antibody has a sequence having at least 90% identity to the sequence of

5 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSAQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
10 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

In some embodiments, the heavy chain variable region of an isolated antibody has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
15 FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
20 QYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

In some embodiments, the heavy chain variable region of an isolated antibody has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
25 GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
QYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
30 RWQQGNVFSCSVMEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

30 In other embodiments, the heavy chain variable region of an isolated antibody has a sequence having at least 90% identity to the sequence of
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS
35 NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREGQ
QYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
RWQQGNVFSCSVMEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

40 In yet other embodiments, the heavy chain variable region of an isolated antibody has a sequence having at least 90% identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
5 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

The disclosure features an isolated antibody including a light chain variable region and a heavy chain variable region, where the light chain variable region has a sequence having at least 90% identity to
10 the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAEADYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
15 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90%

15 identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
20 VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

The disclosure features an isolated antibody including a light chain variable region and a heavy chain variable region, where the light chain variable region has a sequence having at least 90% identity to
25 the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAEADYYCSSLYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQCQVTHEGSTVEK
25 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90%

30 identity to the sequence of

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
35 YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

The disclosure features an isolated antibody including a light chain variable region and a heavy chain variable region, where the light chain variable region has a sequence having at least 90% identity to
40 the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90%

5 identity to the sequence of

EVQLLESGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
10 YVDGVEVHNNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

The disclosure features an isolated antibody including a light chain variable region and a heavy chain variable region, where the light chain variable region has a sequence having at least 90% identity to

15 the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90%

20 identity to the sequence of

EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
25 YVDGVEVHNNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

The disclosure features an isolated antibody including a light chain variable region and a heavy chain variable region, where the light chain variable region has a sequence having at least 90% identity to

30 the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has a sequence having at least 90%

35 identity to the sequence of

EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTWSNSGALTSGVHTFPALQSSGLYSLSSVTPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
40 VDGVEVHNNAKTKPREEQYASTYRVVSVLVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ

VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDGSFFLYSKLTVDKSR
WQQGNVFCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

Furthermore, in any of the anti-FcRn antibodies described herein, the heavy chain variable region of the antibody has a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of any 5 one of SEQ ID NOs: 20-24. In any of the anti-FcRn antibodies described herein, the light chain variable region has a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of SEQ ID NO: 19.

The antibodies may further contain amino acid substitutions, additions, and/or deletions outside 10 of the CDRs (i.e., in framework regions (FRs)). An amino acid substitution, addition, and/or deletion can be a substitution, addition, and/or deletion of one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or more). An amino acid substitution, addition, and/or deletion can be a substitution, addition, and/or deletion of 15 eight or fewer, seven or fewer, six or fewer, five or fewer, four or fewer, three or fewer, or two or fewer single amino acids. In some embodiments, the antibodies may further include any one or more of the following amino acid substitutions: A23V, S30R, L80V, A84T, E85D, A93V, relative to the sequence of any one of SEQ ID NOs: 20-24, and Q38H, V58I, and G99D, relative to the sequence of SEQ ID NO: 19.

In some embodiments, the antibodies may include amino acid substitutions, additions, and/or 20 deletions in the constant regions (e.g., Fc region) of the antibody that, e.g., lead to decreased effector function, e.g., decreased complement-dependent cytosis (CDC), antibody-dependent cell-mediated cytosis (ADCC), and/or antibody-dependent cell-mediated phagocytosis (ADCP), and/or decreased B-cell killing. The constant regions are not involved directly in binding an antibody to its target, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity. In some embodiments, the antibodies are characterized by decreased binding (i.e., absence of binding) to 25 human complement factor C1q and/or human Fc receptor on natural killer (NK) cells. In other embodiments, the antibodies are characterized by decreased binding (i.e., absence of binding) to human Fc_YRI, Fc_YRIIA, and/or Fc_YRIIA. To alter or reduce an antibody-dependent effector function, such as CDC, ADCC, ADCP, and/or B-cell killing, antibodies may be of the IgG class and contain one or more amino acid substitutions E233, L234, G236, D265, D270, N297, E318, K320, K322, A327, A330, P331, and/or P329 (numbering according to the EU index of Kabat (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991))). In some 30 embodiments, the antibodies contain the mutations L234A/L235A or D265A/N297A. Preferably, an anti-FcRn antibody contains amino acid substitution N297A, relative to the sequence of any one of SEQ ID NOs: 20-24, such that the antibody is changed to an aglycosylated form. The resulting effectorless antibody shows very little binding to complement or Fc receptors (i.e., complement C1q binding), indicating low CDC potential.

35 In other embodiments, the antibodies may include those having specific amino acid changes that improve stability of the antibody.

Moreover, in other embodiments, to minimize potential immunogenicity, some antibodies, e.g., N024, N026, and N027, may undergo an allotype change from G1m17.1 to G1m17 by substituting amino acids D355 and L357 (relative to the sequence of any one of SEQ ID NOs: 20-24) to glutamic acid and 40 methionine, respectively.

In other embodiments, the antibodies, e.g., N022-N024, N026, and N027, do not contain a C-terminal lysine, e.g., a C-terminal lysine at residue 446 relative to the sequence of any one of SEQ ID NOs: 20-24.

The disclosure features an isolated antibody containing a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of
5 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
10 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGSSGAQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
15 VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 20).

The disclosure features an isolated antibody containing a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
20 GNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
25 GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
YVDGVEVHNAAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSRW
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 21).

30 The disclosure features an isolated antibody containing a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFGSKS
GNTASLTISGLQAEDAEADYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEK
35 TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYAMGWVRQAPGKGLEWVSSIGASGAQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
40 YVDGVEVHNAAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP

QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 22).

The disclosure features an isolated antibody containing a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of

5 QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
10 EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGGQTRYADSVKGR
FTISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPS
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP
15 QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 23).

The disclosure features an isolated antibody containing a light chain variable region and a heavy chain variable region, wherein the light chain variable region has the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDeadYYCSSYAGSGIYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLI
20 SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and the heavy chain variable region has the sequence of
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
25 TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VVGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKS
WQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

In yet other embodiments, the antibodies are sialylated antibodies.

30 In any of the anti-FcRn antibodies described herein, in some embodiments, the antibody binds mouse or rat FcRn with a K_D of less than 200, 150, 100, 50, or 40 pM.

In any of the anti-FcRn antibodies described herein, in some embodiments, the antibody binds to human FcRn with an affinity of between 1-100, 5-150, 5-100, 5-75, 5-50, 10-50, or 10-40 pM.

The anti-FcRn antibodies may be of immunoglobulin antibody isotype IgG, IgE, IgM, IgA, or IgD.

35 Preferably, the anti-FcRn antibodies are of immunoglobulin antibody isotype IgG. The anti-FcRn antibodies may also be of any immunoglobulin antibody isotype subclasses. For example, the anti-FcRn antibodies may be of IgG subclass IgG1, IgG2, IgG3, or IgG4. Preferably, the anti-FcRn antibodies are of subclass IgG1. In particular, the anti-FcRn antibodies contain an IgG G1m17 or G1m17.1 allotype heavy chain. In some embodiments, the light chain of the anti-FcRn antibodies may be a κ light chain, a λ light

chain, or a κ - λ chimeric light chain. In preferred embodiments, the anti-FcRn antibodies contain a full-length λ light chain.

In some embodiments, the antibodies (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) are monoclonal. The antibodies may also be polyclonal, chimeric, humanized or fully 5 human. In some embodiments, the antibody may be affinity matured. In other embodiments, the antibody may be an antibody fragment.

Without being bound by theory, it is believed that the anti-FcRn antibodies compete with and inhibit the binding of IgG to human FcRn. Epitope mapping by hydrogen-deuterium exchange of the antibodies indicates that the antibodies bind to an epitope on FcRn located in and/or adjacent to the Fc-10 FcRn interaction interface, which suggests that the antibodies block IgG binding to FcRn by direction inhibition. Furthermore, the epitope-mapped binding site is distant from the albumin-binding site of FcRn.

In some embodiments, serum albumin binding is not inhibited. In some cases serum albumin levels are not decreased after anti-FcRn antibody administration.

15 II. Sialylated anti-FcRn antibodies

In some embodiments, the glycosylation site of the Fc region of anti-FcRn antibodies is at least 25%, 50%, 75% or more sialylated, on a mole basis. The antibodies may be sialylated with a sialyltransferase (ST6 Gal-I), which sialylates a substrate in an ordered fashion. Specifically, under 20 certain conditions, ST6 sialyltransferase catalyzes addition of a sialic acid on the α 1,3 arm of glycans on the Fc region of anti-FcRn antibodies, followed by addition of a second sialic acid on the α 1,6 arm, followed by removal of sialic acid from the α 1,3 arm.

Isolated anti-FcRn antibodies may be sialylated during production in the manufacturing host cells (e.g., mammalian cells, e.g., mammalian cells co-transfected with –or overexpressing –an ST6 sialyltransferase). In other embodiments, isolated anti-FcRn antibodies may be sialylated in vitro, post 25 purification from the manufacturing host cell, e.g., enzymatically or through chemical conjugation. Methods of producing sialylated anti-FcRn antibodies are described in PCT Publication WO2014/179601.

III. FcRn inhibition

Human neonatal Fc receptor (FcRn) is a type I transmembrane protein that functions as an IgG-30 and serum albumin-binding, intracellular-IgG trafficking protein. FcRn is expressed in endothelial cells, luminal epithelial cells, hepatocytes, podocytes, granulocytes, monocytes, macrophages, dendritic cells, and NK cells, but not on B or T cells. FcRn maintains the half-life of IgG by binding and trafficking constitutively internalized IgG back to the cell surface. Binding of both Fc and serum albumin by FcRn occurs in the early endosome at pH 6.0, followed by sorting of the FcRn into vesicles, which traffic the 35 FcRn-bound IgG and/or albumin back to the cell surface where FcRn rapidly releases the IgG and/or albumin at pH 7.4. This trafficking cycle maintains the half-life of IgG and albumin by recycling both into the circulation and preventing trafficking to the lysosomes for degradation. FcRn also captures internalized IgG Fc in epithelial cells and transports them bidirectionally to the opposing apical or basolateral membranes. This function allows IgG to traffic to the lumen of organs such as the

gastrointestinal tract or the transport of IgG or IgG-antigen complexes from the lumen to the vasculature or lymphoid tissues in the stromal layers.

In order to study the contribution of FcRn to IgG homeostasis, mice have been engineered so that parts of the light and heavy chains of FcRn have been “knocked out” so that these proteins are not expressed (Junghans et al., *Proc Natl Acad Sci USA* 93:5512, 1996). In these mice, the serum half-life and concentrations of IgG were dramatically reduced, suggesting an FcRn-dependent mechanism of IgG homeostasis. Studies in rodent models, such as the one discussed above, suggest that blockage of FcRn function can increase IgG catabolism, including that of pathogenic autoantibodies, thereby inhibiting disease (e.g., an autoimmune disease) development. FcRn may also contribute to antigen presentation through trafficking of immune complexes to antigen degradation and MHC loading compartments.

Placental transfer of maternal IgG antibodies to the fetus is an important FcRn-dependent mechanism that provides protection to the neonate while his/her humoral response is inefficient. During fetal life, FcRn in the syncytiotrophoblast layers of the placenta is responsible for the transfer of maternal IgG antibodies to the fetus. Pathogenic maternal antibodies (e.g., pathogenic maternal IgG antibodies) may also cross the placenta by binding to FcRn and cause alloimmune disorders and/or autoimmune disorders in the fetus and neonate. In some embodiments, pathogenic antibodies in the pregnant subject cause a fetal and neonatal alloimmune and/or autoimmune disorder in a fetus in the pregnant subject. The anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) may compete with and inhibit the binding of maternal pathogenic antibodies (e.g., maternal pathogenic IgG antibodies) to FcRn, thereby increasing the catabolism and decreasing the half-life of these pathogenic antibodies.

The present disclosure provides isolated anti-FcRn antibodies that bind to human FcRn. The anti-FcRn antibodies may compete with and inhibit the binding of other anti-FcRn antibodies (e.g., IgG, IgG autoantibodies) to FcRn, thereby increasing the catabolism and decreasing the half-life of other anti-FcRn antibodies (e.g., IgG, IgG autoantibodies). The anti-FcRn antibodies may be used in a method of treating or reducing immune complex-based activation of an immune response in a subject, such as an immune response caused by autoantibodies in an autoimmune disease. Reducing an immune response may be described as reducing an immune response relative to a subject who does not receive treatment (e.g., a control subject). The anti-FcRn antibodies may also be used in methods of decreasing pathogenic antibody transport (e.g., pathogenic maternal IgG antibody transport) across the placenta of a pregnant subject, increasing pathogenic antibody catabolism in a pregnant subject, and treating an antibody-mediated enhancement of viral disease in a fetus or a neonate by administering to a pregnant subject an isolated antibody that binds to human FcRn. Decreasing pathogenic antibody transport across the placenta of a pregnant subject, may be described as decreasing pathogenic antibody transport relative to a subject who does not receive treatment (e.g., a control subject).

IV. Vectors, host cells, and antibody production

The anti-FcRn antibodies can be produced from a host cell. A host cell refers to a vehicle that includes the necessary cellular components, e.g., organelles, needed to express the polypeptides and constructs described herein from their corresponding nucleic acids. The nucleic acids may be included in

nucleic acid vectors that can be introduced into the host cell by conventional techniques known in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, etc.). The choice of nucleic acid vectors depends in part on the host cells to be used.

Generally, preferred host cells are of either prokaryotic (e.g., bacterial) or eukaryotic (e.g., mammalian)

5 origin.

Nucleic acid vector construction and host cells

A nucleic acid sequence encoding the amino acid sequence of an anti-FcRn antibody may be prepared by a variety of methods known in the art. These methods include, but are not limited to,

10 oligonucleotide-mediated (or site-directed) mutagenesis and PCR mutagenesis. A nucleic acid molecule encoding an anti-FcRn antibody may be obtained using standard techniques, e.g., gene synthesis.

Alternatively, a nucleic acid molecule encoding a wild-type anti-FcRn antibody may be mutated to contain specific amino acid substitutions using standard techniques in the art, e.g., QuikChange™ mutagenesis. Nucleic acid molecules can be synthesized using a nucleotide synthesizer or PCR techniques.

15 Nucleic acid sequences encoding anti-FcRn antibodies may be inserted into a vector capable of replicating and expressing the nucleic acid molecules in prokaryotic or eukaryotic host cells. Many vectors are available in the art and can be used. Each vector may contain various components that may be adjusted and optimized for compatibility with the particular host cell. For example, the vector components may include, but are not limited to, an origin of replication, a selection marker gene, a

20 promoter, a ribosome binding site, a signal sequence, the nucleic acid sequence encoding protein of interest, and a transcription termination sequence.

In some embodiments, mammalian cells are used as host cells. Examples of mammalian cell types include, but are not limited to, human embryonic kidney (HEK) (e.g., HEK293, HEK 293F), Chinese hamster ovary (CHO), HeLa, COS, PC3, Vero, MC3T3, NS0, Sp2/0, VERY, BHK, MDCK, W138, BT483, 25 Hs578T, HTB2, BT20, T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, and HsS78Bst cells. In other embodiments, *E. coli* cells are used as host cells. Examples of *E. coli* strains include, but are not limited to, *E. coli* 294 (ATCC® 31,446), *E. coli* λ 1776 (ATCC® 31,537), *E. coli* BL21 (DE3) (ATCC® BAA-1025), and *E. coli* RV308 (ATCC® 31,608).

Different host cells have characteristic and specific mechanisms for the posttranslational processing and 30 modification of protein products. Appropriate cell lines or host systems may be chosen to ensure the correct modification and processing of the anti-FcRn antibody expressed. The above-described expression vectors may be introduced into appropriate host cells using conventional techniques in the art, e.g., transformation, transfection, electroporation, calcium phosphate precipitation, and direct microinjection. Once the vectors are introduced into host cells for protein production, host cells are 35 cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Methods for expression of therapeutic proteins are known in the art, see, for example, Paulina Balbas, Argelia Lorence (eds.) *Recombinant Gene Expression: Reviews and Protocols (Methods in Molecular Biology)*, Humana Press; 2nd ed. 2004 (July 20, 2004) and Vladimir Voynov and Justin A. Caravella (eds.) *Therapeutic Proteins: 40 Methods and Protocols (Methods in Molecular Biology)* Humana Press; 2nd ed. 2012 (June 28, 2012).

Protein production, recovery, and purification

Host cells used to produce the anti-FcRn antibodies may be grown in media known in the art and suitable for culturing of the selected host cells. Examples of suitable media for mammalian host cells 5 include Minimal Essential Medium (MEM), Dulbecco's Modified Eagle's Medium (DMEM), Expi293™ Expression Medium, DMEM with supplemented fetal bovine serum (FBS), and RPMI-1640. Examples of suitable media for bacterial host cells include Luria broth (LB) plus necessary supplements, such as a selection agent, e.g., ampicillin. Host cells are cultured at suitable temperatures, such as from about 20 °C to about 39 °C, e.g., from 25 °C to about 37 °C, preferably 37 °C, and CO₂ levels, such as 5 to 10% 10 (preferably 8%). The pH of the medium is generally from about 6.8 to 7.4, e.g., 7.0, depending mainly on the host organism. If an inducible promoter is used in the expression vector, protein expression is induced under conditions suitable for the activation of the promoter.

Protein recovery typically involves disrupting the host cell, generally by such means as osmotic 15 shock, sonication, or lysis. Once the cells are disrupted, cell debris may be removed by centrifugation or filtration. The proteins may be further purified. An anti-FcRn antibody may be purified by any method known in the art of protein purification, for example, by protein A affinity, other chromatography (e.g., ion exchange, affinity, and size-exclusion column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. (see *Process Scale Purification of Antibodies*, Uwe Gottschalk (ed.) John Wiley & Sons, Inc., 2009). In some instances, an anti-FcRn 20 antibody can be conjugated to marker sequences, such as a peptide to facilitate purification. An example of a marker amino acid sequence is a hexa-histidine peptide (His-tag), which binds to nickel-functionalized agarose affinity column with micromolar affinity. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein.

25 Alternatively, anti-FcRn antibodies can be produced by the cells of a subject (e.g., a human), e.g., in the context of therapy, by administrating a vector (e.g., a retroviral vector, adenoviral vector, poxviral vector (e.g., vaccinia viral vector, such as Modified Vaccinia Ankara (MVA)), adeno-associated viral vector, and alphaviral vector) containing a nucleic acid molecule encoding the anti-FcRn antibody. The vector, once inside a cell of the subject (e.g., by transformation, transfection, electroporation, calcium 30 phosphate precipitation, direct microinjection, infection, etc.) will promote expression of the anti-FcRn antibody, which is then secreted from the cell. If treatment of a disease or disorder is the desired outcome, no further action may be required. If collection of the protein is desired, blood may be collected from the subject and the protein purified from the blood by methods known in the art.

35 **V. Pharmaceutical compositions and preparations**

The disclosure features pharmaceutical compositions that include one or more anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024). In some 40 embodiments, pharmaceutical compositions contain one or more antibodies as the therapeutic proteins. In other embodiments, pharmaceutical compositions containing one or more antibodies may be used in combination with other agents (e.g., therapeutic biologics and/or small molecules) or compositions in a

therapy. In addition to a therapeutically effective amount of the antibody, the pharmaceutical compositions may contain one or more pharmaceutically acceptable carriers or excipients, which can be formulated by methods known to those skilled in the art.

Acceptable carriers and excipients in the pharmaceutical compositions are nontoxic to recipients at the dosages and concentrations employed. Acceptable carriers and excipients may include buffers, antioxidants, preservatives, polymers, amino acids, and carbohydrates. Pharmaceutical compositions can be administered parenterally in the form of an injectable formulation. Pharmaceutical compositions for injection (i.e., intravenous injection) can be formulated using a sterile solution or any pharmaceutically acceptable liquid as a vehicle. Pharmaceutically acceptable vehicles include, but are not limited to, sterile water, physiological saline, and cell culture media (e.g., Dulbecco's Modified Eagle Medium (DMEM), α-Modified Eagles Medium (α-MEM), F-12 medium). Formulation methods are known in the art, see e.g., Banga (ed.) *Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems* (2nd ed.) Taylor & Francis Group, CRC Press (2006).

The pharmaceutical composition may be formed in a unit dose form as needed. The amount of active component, e.g., one or more anti-FcRn antibodies (e.g., N022-N024, N026, and N027, preferably N027 and/or N024), included in the pharmaceutical preparations is such that a suitable dose within the designated range is provided (e.g., a dose within the range of 0.01-500 mg/kg of body weight).

VI. Routes, dosage, and administration

Pharmaceutical compositions that contain one or more anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) as the therapeutic proteins may be formulated for intravenous administration, parenteral administration, subcutaneous administration, intramuscular administration, intra-arterial administration, intrathecal administration, or intraperitoneal administration. In particular, intravenous administration is preferred. The pharmaceutical composition may also be formulated for, or administered via, oral, nasal, spray, aerosol, rectal, or vaginal administration. For injectable formulations, various effective pharmaceutical carriers are known in the art.

The dosage of the pharmaceutical compositions depends on factors including the route of administration, the disease to be treated, and physical characteristics, e.g., age, weight, general health, of the subject. Typically, the amount of an anti-FcRn antibody described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) contained within a single dose may be an amount that effectively prevents, delays, or treats the disease without inducing significant toxicity. A pharmaceutical composition may include a dosage of an anti-FcRn antibody ranging from 0.01 to 500 mg/kg (e.g., 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg/kg) and, in a more specific embodiment, about 1 to about 100 mg/kg and, in a more specific embodiment, about 1 to about 50 mg/kg. The dosage may be adapted by the physician in accordance with conventional factors such as the extent of the disease and different parameters of the subject.

The pharmaceutical compositions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective to result in an improvement or remediation of the symptoms. The pharmaceutical compositions are administered in a variety of dosage forms, e.g.,

intravenous dosage forms, subcutaneous dosage forms, and oral dosage forms (e.g., ingestible solutions, drug release capsules). Generally, therapeutic proteins are dosed at 1-100 mg/kg, e.g., 1-50 mg/kg. Pharmaceutical compositions that contain an anti-FcRn antibody described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) may be administered to a subject in need thereof, for 5 example, one or more times (e.g., 1-10 times or more) daily, weekly, monthly, biannually, annually, or as medically necessary. Dosages may be provided in either a single or multiple dosage regimens. The timing between administrations may decrease as the medical condition improves or increase as the health of the patient declines.

10 **VII. Methods of Treatment and Indications**

The blockade of human FcRn by anti-FcRn antibodies may be of therapeutic benefit in diseases that are driven by IgG autoantibodies. The ability of FcRn blockade to induce overall pathogenic antibody (e.g., an IgG antibody) catabolism and removal of multiple species of autoantibodies without perturbing serum albumin, small circulating metabolites, or lipoproteins offers a method to expand the utility and 15 accessibility of an autoantibody removal strategy to patients with autoantibody-driven autoimmune disease pathology. While this disclosure is not bound by theory, the dominant mechanism of action of an anti-FcRn antibody may be to increase the catabolism of pathogenic autoantibodies in circulation and decrease autoantibody and immune complex deposition in affected tissues.

The pharmaceutical compositions and methods containing one or more anti-FcRn antibodies 20 described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) are useful to promote catabolism and clearance of pathogenic antibodies, e.g., IgG and IgG autoantibodies in a subject, to reduce the immune response, e.g., to block immune complex-based activation of the immune response in a subject, and to treat immunological conditions or diseases in a subject. In particular, the pharmaceutical compositions and methods are useful to reduce or treat an immune complex-based 25 activation of an acute or chronic immune response. The acute immune response may be activated by a medical condition selected from the group consisting of pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura (ITP), autoimmune haemolytic anaemia 30 (AIHA), immune neutropenia, dialated cardiomyopathy, and serum sickness. The chronic immune response may be activated by a medical condition selected from the group consisting of chronic inflammatory demyelinating polyneuropathy (CIDP), systemic lupus, a chronic form of a disorder indicated for acute treatment, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

35 In some embodiments, the pharmaceutical compositions and methods are useful to decrease the risk of or decrease the risk of developing anemia in the fetus. In some embodiments, the pharmaceutical compositions and methods are useful to decrease or obviate the need for IUT (intrauterine transfusion). In some embodiments, the pharmaceutical compositions and methods are useful to decrease or obviate the need for antenatal PP + IVIg, postnatal transfusion, IVIg, and/or phototherapy. In some embodiments, 40 the pharmaceutical compositions and methods are useful to reduce or treat an immune response

activated by an autoimmune disease. The autoimmune disease may be selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcets disease, bullous pemphigoid, cardiomopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic 5 inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen 10 planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's 15 granulomatosis.

In particular, the pharmaceutical compositions and methods are useful to reduce or treat an immune response activated by systemic lupus erythematosus, antiphospholipid syndrome, pemphigus vulgaris/bullous pemphigoid, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, myasthenia gravis, or neuromyelitis optica.

20 The pharmaceutical compositions and methods are useful in methods of decreasing pathogenic antibody transport (e.g., pathogenic maternal IgG antibody transport) across the placenta of a pregnant subject, increasing pathogenic antibody catabolism in a pregnant subject, and treating an antibody-mediated enhancement of viral disease in a fetus or a neonate by administering to a pregnant subject an isolated antibody that binds to human FcRn. Diseases and disorders that may benefit from FcRn 25 inhibition by the isolated anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) include diseases and disorders in a fetus and/or neonate that are caused by the transfer of maternal pathogenic antibodies (e.g., maternal pathogenic IgG antibodies) across the placenta from a pregnant subject to the fetus and/or neonate.

30 In some embodiments, the diseases and disorders that may benefit from FcRn inhibition by the isolated anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) are fetal and neonatal alloimmune and/or autoimmune disorders. Fetal and neonatal alloimmune disorders are disorders in a fetus and/or neonate that is caused by pathogenic antibodies in the pregnant subject. The pathogenic antibodies in the pregnant subject may attack the antigens of the fetus (e.g., antigens the fetus inherited from the fetus' father), causing the fetus or the neonate to have a 35 fetal and neonatal alloimmune and/or autoimmune disorder.

35 Examples of fetal and neonatal alloimmune and/or autoimmune disorders that may be treated by the methods described herein include, but are not limited to, fetal and neonatal alloimmune thrombocytopenia (FNAIT), hemolytic disease of the fetus and newborn (HDFN), alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal 40 autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis,

dermatomyositis, neonatal lupus, neonatal scleroderma. Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.

In some embodiments, the diseases and disorders that may benefit from FcRn inhibition by the isolated anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) are viral diseases wherein antibodies facilitate viral entry into host cells, leading to increased or enhanced infectivity in the cells, e.g., antibody-mediated enhancement of viral disease. In some embodiments, an antibody may bind to a viral surface protein and the antibody/virus complex may bind to an FcRn on a cell surface through interaction between the antibody and the receptor.

Subsequently, the antibody/virus complex may get internalized into the cell. For example, a virus may gain entry into the cells and/or tissues of a fetus through forming a complex with a maternal IgG antibody. A maternal IgG antibody may bind to a viral surface protein and the IgG/virus complex may bind to an FcRn in the syncytiotrophoblasts of the placenta, which then transfers the complex into the fetus.

In some embodiments, the methods described herein may be used to treat an antibody-mediated enhancement of viral disease. In some embodiments, the viral diseases that are enhanced by pathogenic antibodies (e.g., pathogenic IgG antibodies) include, but are not limited to, viral diseases caused by an alpha virus infection, flavivirus infection, Zika virus infection, Chikungunya virus infection, Ross River virus infection, severe acute respiratory syndrome coronavirus infection, Middle East respiratory syndrome, avian influenza infection, influenza virus infection, human respiratory syncytial virus infection, Ebola virus infection, yellow fever virus infection, dengue virus infection, human immunodeficiency virus infection, respiratory syncytial virus infection, Hantavirus infection, Getah virus infection, Sindbis virus infection, Bunyamwera virus infection, West Nile virus infection, Japanese encephalitis virus B infection, rabbitpox virus infection, lactate dehydrogenase elevating virus infection, reovirus infection, rabies virus infection, foot-and-mouth disease virus infection, porcine reproductive and respiratory syndrome virus infection, simian hemorrhagic fever virus infection, equine infectious anemia virus infection, caprine arthritis virus infection, African swine fever virus infection, lentivirus infection, BK papovavirus infection, Murray Valley encephalitis virus infection, enterovirus infection, cytomegalovirus infection, pneumovirus infection, morbillivirus infection, and measles virus infection.

The blockade of human FcRn by anti-FcRn antibodies may be of therapeutic benefit in diseases that are driven by pathogenic antibodies (e.g., pathogenic IgG antibodies). The ability of FcRn blockade to induce overall pathogenic antibody catabolism and removal of multiple species of pathogenic antibodies without perturbing serum albumin, small circulating metabolites, or lipoproteins offers a method to expand the utility and accessibility of a pathogenic antibody removal strategy to patients with pathogenic antibody-driven autoimmune disease pathology. While not bound by theory, the dominant mechanism of action of an anti-FcRn antibody may be to increase the catabolism of pathogenic antibodies in circulation and decrease pathogenic antibody and immune complex deposition in affected tissues.

The anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) may be administered to a pregnant subject who has or is at risk of having a medical condition that activates an immune response in the pregnant subject. In some embodiments, the pregnant subject may have had, in the past, a medical condition that activated an immune response in

the pregnant subject. In some embodiments, the pregnant subject has a history of having had a previous fetus or neonate that had a fetal and neonatal alloimmune and/or autoimmune disorder. In some embodiments, the anti-FcRn antibodies described herein may be administered to a pregnant subject if a pathogenic antibody associated with an immune disease is detected in a biological sample (e.g., a blood 5 or urine sample) obtained from the pregnant subject. In some embodiments, the pathogenic antibody detected in the biological sample of the pregnant subject is known to bind to an antigen from the fetus in the pregnant subject (e.g., an antigen that the fetus inherited from the fetus' father).

In some embodiments, the anti-FcRn antibodies described herein (e.g., N022-N024, N026, and N027, preferably N027 and/or N024) may be administered to a subject who is planning to become 10 pregnant and who has or is at risk of having a medical condition that activates an immune response in the pregnant subject, and/or who has had, in the past, a medical condition that activated an immune response in the pregnant subject. In some embodiments, a subject is planning to become pregnant and has a history of having had a previous fetus or neonate that had a fetal and neonatal alloimmune and/or autoimmune disorder. In some embodiments, the anti-FcRn antibodies described herein may be 15 administered to a subject who is planning to become pregnant and whose biological sample contains a pathogenic antibody associated with an immune disease.

In some embodiments, the anti-FcRn antibodies described herein may be administered to a subject (e.g., a pregnant subject) to reduce or treat an immune complex-based activation of an acute or 20 chronic immune response in the subject. The acute immune response may be activated by a medical condition (e.g., pemphigus vulgaris, lupus nephritis, myasthenia gravis, Guillain-Barré syndrome, antibody-mediated rejection, catastrophic anti-phospholipid antibody syndrome, immune complex-mediated vasculitis, glomerulitis, a channelopathy, neuromyelitis optica, autoimmune hearing loss, idiopathic thrombocytopenia purpura, autoimmune haemolytic anaemia, immune neutropenia, dialated 25 cardiomyopathy, serum sickness, chronic inflammatory demyelinating polyneuropathy, systemic lupus, reactive arthropathies, primary biliary cirrhosis, ulcerative colitis, or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis).

In some embodiments, the anti-FcRn antibodies described herein may be administered to a subject (e.g., a pregnant subject) to reduce or treat an immune response activated by an autoimmune disease. The autoimmune disease may be, for example, alopecia areata, ankylosing spondylitis, 30 antiphospholipid syndrome, Addison's disease, hemolytic anemia, warm autoimmune hemolytic anemia (wAIHA), anti-factor antibodies, heparin induced thrombocytopenia (HICT), sensitized transplant, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST 35 syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, 40 polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary

agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, or Wegener's granulomatosis.

5

EXAMPLES

Example 1 – Antibody production

IgG heavy and light chain nucleic acid molecules were cloned in vector pCDNA 3.3 using osteonectin secretion signals. HEK 293F cells were grown in Expi293 media at 37 °C with 8% CO₂. Cells were transfected at a density of 3x10⁶/ml with 1 mg total DNA per liter. Enhancers were added on 10 days 2 and 3 following manufacturer's directions and the cells were cultured until day 5 or 6 before cell viability dropped to below 50% to 60%. The cells were then spun out by centrifugation and the spent media was sterile filtered and stored at 4 °C until antibody purification. Antibodies were purified by a two-column procedure: POROS Protein A chromatography followed by POROS HS-50 cation exchange chromatography. The former separated most of the host cell proteins from the expressed antibodies 15 while the latter removed the heavy chain dimers, light chain dimers, and half antibodies, as well as higher molecular weight species. The fractions from the HS-50 cation exchange column were pooled based on an SDS-PAGE gel analysis to maximize purity of the full-length antibodies. The collected fractions were put over a Sephadex G50 buffer exchange column equilibrated in PBS at pH 7.2. The peak fractions 20 were pooled and concentrated to greater than 10 mg/ml using 30 kDa spin concentrators and frozen at -30 °C in 2 mg and 5 mg aliquots. The final protein samples were checked for purity by SDS-PAGE.

Example 2 – Binding affinities

Through affinity maturation, we identified more than 100 anti-FcRn antibodies having binding affinities to human FcRn with a K_D in the sub-micromolar range. Five antibodies (N022-N024, N026, and 25 N027) were selected for further characterization. Surface Plasmon Resonance (SPR) was used to determine the on- and off-rates (k_a and k_d, respectively) for each of these five antibodies. Briefly, a Bio-Rad GLC sensor chip was inserted into the ProteOn XPR 36 and air initialized. After initialization the running buffer was switched to freshly prepared buffer, either HBSP+ (0.01 M HEPES, 0.15 M NaCl, 0.05% P20, pH 7.4) or Sodium Phosphate Buffer (0.02 M Sodium Phosphate, 0.15 M NaCl, 0.05% P20, 30 pH 6.0) as appropriate, which was used for the remainder of the assay and for all dilutions. The chip was preconditioned using one injection each of 0.5% SDS, 50mM NaOH and 10mM HCl at 30 µl/min for 60 seconds (s). A mouse anti-Human Fc mAb from GE Healthcare (BR100839) was diluted to 10 µg/ml in 10 mM acetate buffer pH 5.0 and approximately 5,700 response units (RU) was immobilized using standard amine coupling chemistry in the horizontal orientation onto a GLC sensor chip. The anti-hFcRn 35 mAbs to be tested were captured onto the surface in the vertical orientation, with the goal of immobilizing approximately 200 response units (RU) per interaction spot. The rhFcRn was diluted in a five-point three-fold dilution series starting at 1.25 µg/ml, leaving one lane as buffer-only for a double reference. The analyte was flowed across the sensor surface in the horizontal orientation at 100 µl/min for 240 s with a 3,600 s dissociation time. Regeneration was accomplished by injecting 3M MgCl₂ at 100 µl/min for 30 s 40 in both the horizontal and vertical directions. These procedures were repeated for all ligands.

5 Data analysis was conducted using the ProteOn Manager software. Each interaction step was adjusted for the Y and X direction using the Auto Process tool, followed by interspot channel referencing to remove non-specific interactions and blank lane double referencing to remove assay drift. The data was fit using the Langmuir 1:1 kinetic model with a grouped Rmax. The k_a , k_d and K_D values obtained from ProteOn Manager in a single run were averaged and their percent CV was calculated in Microsoft Excel when the N was three or greater.

10 Table 3 shows that five anti-FcRn antibodies, N022, N023, N024, N026, and N027, all bind with high affinity to human FcRn at pH 7.4. The equilibrium dissociation constant, K_D , of the anti-FcRn antibodies ranged from 19.4 pM (N027) to 36.5 pM (N026) for binding to human FcRn at pH 7.4, 298K. Table 3 also shows the rapid on-rates and slow off-rates of the five anti-FcRn antibodies. At pH 7.4, 298K, the on-rates were in the range of $0.93\text{-}1.42 \times 10^6$ 1/Ms for binding to human FcRn. The off-rates were in the range of $2.31\text{-}4.44 \times 10^6$ 1/s.

Table 3

	k_a (1/Ms)	k_d (1/s)	K_D (M)	R_{max}	Chi2	K_D (pM)
N022	1.42E+06	4.42E-05	3.10E-11	146.93	7.65	31
N023	9.27E+05	2.91E-05	3.14E-11	193.43	5.26	31.4
N024	1.13E+06	4.03E-05	3.55E-11	181.17	6.12	35.5
N026	1.22E+06	4.44E-05	3.65E-11	163.9	5.68	36.5
N027	1.19E+06	2.31E-05	1.94E-11	211.33	7.81	19.4

15

Example 3 – IgG competition

20 The ability of anti-FcRn antibodies to compete with IgG for binding to human or cynomolgus monkey FcRn was evaluated on human embryonic kidney (HEK) 293 cells ectopically expressing cell surface, glycoprophosphatidylinositol (GPI)-linked FcRn. Human and cynomolgus monkey FcRn alpha amino acid sequences exhibit 97.5% sequence identity. Nine amino acid residues of 355 are different between human and cynomolgus monkey FcRn alpha, but none are in the epitope-mapped binding region. The level of cell-bound IgG was determined using 66 nM of fluorescent probe-labeled, non-specific IgG. The binding of IgG to cell surface FcRn was done at pH 6.0, which allows the Fc portion of IgG to interact with FcRn. As shown in FIG. 1, the amount of cell-bound IgG significantly decreased as 25 the concentration of the anti-FcRn antibody (N022-N024, N026, or N027) increased. The binding of IgG was inhibited in a concentration- and saturation-dependent manner by each of the five exemplary anti-FcRn antibodies, demonstrating the ability of the anti-FcRn antibodies, N022-N024, N026, and N027, to effectively compete with and inhibit binding of IgG to FcRn at pH 6.0. The EC50 values of the antibodies ranged between 2 and 6 nM.

30

Example 4 – Effect of anti-FcRn antibodies on IgG catabolism in mice

To measure the effect of the anti-FcRn antibodies on IgG catabolism *in vivo*, human FcRn transgenic mouse strain, homozygous B6.Cg-*Fcgr1tm1Dcr* Tg(FCGRT)32Dcr/DcrJ mice, which lacks mouse FcRn but expresses human FcRn in a tissue distribution similar to the endogenous mouse and human FcRn, was used. FcRn-/hFcRn (32) Tg mice injected with 500 mg/kg human IVIG tracer on day 0 were administered a single dose of an anti-FcRn antibody at 10 mg/kg on days 1 and 4. As shown in FIG. 2, the catabolism of IgG was increased by the administration of anti-FcRn antibodies as seen by lower levels of IgG measured over time in anti-FcRn antibody-treated mice. The activities of N024 ($K_D = 35.5$ pM), N026 ($K_D = 36.5$ pM), and N027 ($K_D = 19.4$ pM) appeared to be similar at 10 mg/kg.

10

Example 5 – *In vitro* characterizations of anti-FcRn antibodies

Cellular binding affinities of the antibodies were measured on human embryonic kidney (HEK) 293 cells ectopically expressing cell surface, glycoprophosphatidylinositol (GPI)-linked human or cynomolgus monkey FcRn. FcRn is a type I transmembrane protein with the IgG and albumin binding domains oriented to the luminal side of endosomal membranes or to the cell surface when transported to the plasma membrane. The binding of anti-FcRn antibodies to cell surface, membrane-associated FcRn on HEK293 cells at pH 7.4 mimics binding in a physiologically-relevant environment and at the pH where only the Fab domain and not the Fc domain of the antibodies interact with FcRn. The FcRn extracellular domain was displayed on the cell surface at high density through a C-terminal engineered GPI linkage.

15 The anti-FcRn antibodies were labeled with a fluorescent probe. The antibodies were allowed to bind for 30 minutes on ice. Cells were then washed at 4 °C and bound antibodies were detected using a fluorophore-labeled secondary antibody, e.g., a goat anti-human IgG F(ab)₂. The binding to human FcRn was concentration dependent and antibodies displayed EC50 values ranging from 4 to 7 nM.

20 Cellular binding affinities of the antibodies were also measured on endogenously expressed human FcRn. Monocytes express the highest levels of FcRn and show the highest percent positivity for FcRn expression in mouse and human blood. Monocytic cell line THP-1 was used to evaluate binding of anti-FcRn antibodies to endogenous human FcRn at pH 7.4. Since endogenous FcRn is primarily in intracellular endosomal vesicles, the THP-1 cells were first fixed and then permeabilized with a mild detergent and fixed prior to incubation for 30 minutes at 4 °C with anti-FcRn antibodies in the presence of 25 bovine serum to block non-specific Fc receptor binding. This assay was able to distinguish antibodies with better binding to endogenous human FcRn. The binding of anti-FcRn antibodies to THP-1 cells is concentration dependent. All antibodies, e.g., N022-N024, N026, and N027, showed better binding affinities than IgG1. Antibody N027 displayed the highest binding affinity with an EC50 value of 3.0 nM.

30 Epitope mapping by hydrogen-deuterium exchange of the antibodies indicated that the antibodies bind to an epitope that comprises at least a portion of two amino acid sequences on human FcRn. One amino acid sequence includes at least one amino acid of the sequence of KQGTWGGDWPEAL (SEQ ID NO: 25), located in and/or adjacent to the Fc-FcRn interaction interface, which suggests that the antibodies block IgG binding to FcRn by direction inhibition. The first amino acid sequence comprises W131 of FcRn (SEQ ID NO: 30). The second amino acid sequence includes at least one amino acid of 35 the sequence of FKALGGKGPYTL (SEQ ID NO: 26). The second amino acid sequence comprises Y88

of FcRn (SEQ ID NO: 30). The epitope of the anti-FcRn antibody includes one or both of a) an amino acid sequence comprising W131 of FcRn and b) an amino acid sequence comprising Y88 of FcRn. In some embodiments, the epitope comprises at least a) an amino acid sequence comprising W131 of FcRn and b) an amino acid sequence comprising Y88 of FcRn. In some embodiments, the epitope comprises 5 either a) an amino acid sequence comprising W131 of FcRn or b) an amino acid sequence comprising Y88 of FcRn. The epitope-mapped binding sites are distant from the albumin-binding site of FcRn. Thus, serum albumin-binding should not be inhibited and serum albumin levels should not be decreased. An enzyme-linked immunosorbent assay (ELISA) was used to confirm that the antibodies do not inhibit 10 serum albumin binding to FcRn. Soluble His-tagged extracellular domain of human FcRn was bound to the plate surface and pre-incubated with increasing concentrations of anti-FcRn antibody at pH 6.0. Horseradish peroxidase (HRP)-conjugated human serum albumin was allowed to bind to the soluble, His-tagged FcRn. None of the antibodies inhibited albumin binding to FcRn. Furthermore, *in vivo* 15 experimental evidence also showed that cynomolgus monkey albumin levels remained constant after anti-FcRn antibody administration, indicating that albumin recycling was not disturbed by antibody binding to FcRn (FIG. 4C).

Example 6 – Effect of anti-FcRn antibodies on IgG levels and target occupancy in mice

N027 was dosed intravenously (i.v.) 24 hrs after administration of 500 mg/kg human IVIg (tracer) to homozygous B6.Cg-*Fcgtr^{tm1Dcr}* Tg(FCGRT)32Dcr/DcrJ mice. Circulating human IgG was detected by 20 ELISA on each day. Target occupancy was measured on each day in monocytes from RBC-lysed whole blood by fluorescence-activated cell sorting (FACS), after incubation of cells with immunophenotyping cell surface markers followed by fixation and permeabilization. Unoccupied FcRn was measured by staining with Dy650-labeled N027 (n = 4 males per group). As shown in FIG. 3, IgG levels and the percentage of 25 unoccupied FcRn were decreased by the administration of N027 in a dose-dependent manner.

Example 7 – Selective induction of IgG catabolism and target occupancy in cynomolgus monkeys

To study the effect of N027 on induction of IgG catabolism and target receptor occupancy, N027 was dosed i.v. on day 0 in cynomolgus monkeys. Circulating endogenous IgG and albumin was detected by ELISA. Target occupancy was measured in monocytes from RBC-lysed whole blood by FACS, after 30 incubation of cells with immunophenotyping cell surface markers followed by fixation and permeabilization. Unoccupied FcRn was measured by staining with Dy650-labeled N027. (n = 3 males per group). As shown in FIGS. 4A-4C, IgG level and the percentage of unoccupied FcRn were decreased by the administration of N027 in a dose-dependent manner, while plasma albumin levels stayed unchanged.

Example 8 – Biodistribution of N027 in mice

To compare the biodistribution of N027 and a human IgG with no target mediated distribution, N027 or human IgG1 isotype control antibody labeled with fluorophore (VivoTag 680) were administered i.v. to homozygous B6.Cg-*Fcgtr^{tm1Dcr}* Tg(FCGRT)32Dcr/DcrJ mice at 30 mg/kg. Levels of labeled 40 antibody were measured in individual organs by quantitative ex vivo fluorescence imaging. As shown in

FIG. 5, the biodistribution of N027 in various organs in mice is similar to that of an isotype control antibody.

Example 9 – Efficacy of N027 in mouse collagen antibody-induced arthritis

5 Collagen antibody-induced arthritis was induced in homozygous B6.Cg-*Fcgrt^{tm1Dcr}* Tg(FCGRT)32Dcr/DcrJ mice by intraperitoneal (i.p.) injection of ArthritoMab™ cocktail (MD Biosciences) on day 1 and inflammatory disease activity induced with 100 µg LPS dosed i.p. on day 4. N027 was dosed therapeutically i.v. at 5 mg/kg (arrow), on day 6 post disease induction and randomization. IVIG at 10 1 g/kg (positive control group) or vehicle-PBS (negative control) were dosed on day 6 after randomization (n = 5 per group). As shown in FIG. 6, N027 potently inhibits collagen antibody-induced arthritis in human transgenic FcRn mice when dosed therapeutically.

Example 10 – Efficacy of N027 in mouse chronic idiopathic thrombocytopenia purpura (ITP)

15 Thrombocytopenia was induced in homozygous B6.Cg-*Fcgrt^{tm1Dcr}* Tg(FCGRT)32Dcr/DcrJ mice by continuous subcutaneous infusion of anti-platelet antibody (anti-CD41, MWReg30) via a miniosmotic pump. Circulating platelet levels were decreased to 300 x 10⁹/L or less by 72 hrs (Day 3) after pump implantation. N027 was dosed therapeutically i.v. 72 hrs (day 3) and 120 hrs (Day 5) post-pump 20 implantation (A, n = 4 per group; B, n = 7 per group). FIG. 7 shows that N027 when dosed therapeutically, can effectively restore platelet levels in mice having thrombocytopenia.

Example 11– Concentration dependent FcRn occupancy was achieved with N027 in target cell types

25 The receptor occupancy by N027 was compared across different cell types such as primary human aortic endothelial cells (HAECS), human umbilical vein endothelial cells (HUVECs) cells and placental trophoblasts (HVTs). Cells were grown to confluence in complete EBM-2 media (Lonza, Waterville) or in trophoblast media (ScienCell). Cell monolayers were incubated in 1 ml of media with 30 different concentrations of unlabeled N027 for 1 hour at 37 °C. After washing, cells were harvested with cold HyQTase, fixed and permeabilized before incubation with VivoTag645-labeled N027 (10 µg/ml), for 30 minutes at 4 °C in the dark. Following incubation, cells were washed with permeabilization buffer before resuspending in FACS buffer. Cell-associated VivoTag645-N027 was measured by flow 35 cytometry. The values represent geometric mean fluorescence intensity (gMFI) ± SD (n=2). FIGS. 8A, 8B, and 8C show the FcRn occupancy across N027 concentrations for the HAECS, HUVECs and HVTs, respectively. The results as summarized in Table 4 show that human ECs (HAECS, HUVECs) as well as placental HVTs exhibit similar concentration dependence receptor occupancy by N027.

35

Table 4

Human Primary Cells	IC ₅₀	100% FcRn occupancy dose
Aortic endothelial cells (HAECS)	0.23 µg/mL	2.43 µg/mL
Venous endothelial cells (HUVECs)	0.15 µg/mL	4.99 µg/mL

Placental trophoblast cells (HVTs)	0.15 µg/mL	2.43 µg/mL
------------------------------------	------------	------------

Example 12 – N027 concentrations achieving 100% receptor occupancy result in increased intracellular IgG accumulation

The relation between levels of receptor occupancy and alterations in IgG intracellular trafficking

5 by N027 was compared across different cell types. Human endothelial cells (HAECs and HUVECs) were cultured in endothelial cell culture (EBM-2, Lonza) while human placental trophoblasts (HVTs) were cultured in trophoblast media (ScienCell). Cell monolayers were then pulsed for 4-5 hours at 37 °C in 1 mL media containing either:

1. varying concentrations of N027 + VivoTag645-IgG (50 µg/mL); or

10 2. varying concentrations of Isotype control IgG + VivoTag645-IgG (50 µg/mL)

Cell monolayers were then washed in cold media followed by cell detachment by HyQtase treatment. Cell associated VivoTag645-N027 was measured by flow cytometry. Values represent geometric mean fluorescence intensity (gMFI) ± SD (n=2). FIGS. 9A, 9B, and 9C show the intracellular IgG levels for the HAECs, HUVECs and HVTs, respectively, corresponding to various doses of N027.

15 N027 doses corresponding to >100% FcRn occupancy resulted in significantly higher IgG accumulation compared to isotype controls. The results demonstrate that the effective N027 concentrations needed to achieve saturating levels of IgG accumulation is similar in these target cell types and ranges from 4.99 to 2.43 µg/mL as summarized in Table 5

Table 5

Human Primary Cells	~IC ₅₀	100% FcRn occupancy dose
Aortic endothelial cells (HAECs)	0.12 µg/mL	2.43 µg/mL
Venous endothelial cells (HUVECs)	0.15 µg/mL	4.99 µg/mL
Placental trophoblast cells (HVTs)	0.07 µg/mL	3.68 µg/mL

20

Example 13 – Measurement of time to 100% FcRn-occupancy

To determine the time taken by N027 to saturate FcRn and block IgG trafficking, confluent

vascular endothelial cell (HUVEC) monolayers were incubated with or without a saturating concentration 25 of N027 (16.6 µg/ml) in EBM-2 media for the indicated times at 37 °C (FIG. 10). Upon completion of incubation, cells were washed and harvested with cold HyQtase, followed by fixing and permeabilization. These cells were then incubated in permeabilization buffer + 10% human serum and VivoTag645-labeled N027 (10 µg/mL) for 30 minutes at 4 °C in the dark. The cells were then washed with permeabilization buffer, resuspended in FACS buffer and cell-associated VivoTag645-N027 was measured by FACS.

30 Values represent mean gMFI ± SD (n=2). The results shown in FIG. 10 indicates that 100% FcRn-occupancy by N027 was achieved in about 30 minutes in this endothelial cell type.

Example 14 – Human vascular endothelial cells and placental trophoblasts exhibit similar FcRn turnover rates which are unaltered by N027

The FcRn turnover rates of human vascular endothelial cells (HUVECs) and placental trophoblasts (HVTs) were compared in the presence and absence of N027. Cells were cultured in 75 cm² flask in 25% D₂O (Deuterium Oxide, from Aldrich) containing media for three days. After three days, the media was replaced with normal media containing N027 (100 µg/mL) or control IgG (100 µg/ml) or mock treatment. Cells were then harvested from the flasks at indicated times post media change (FIGS. 11A and 11B). The cell monolayers were washed; cells were harvested, pelleted, and individual pellets were lysed and digested separately. Shotgun proteomics and targeted proteomics were performed. Using Qual Browser, isotopic relative intensities were extracted and fractional abundances were calculated for each isotopomer by dividing each intensity by the total. Fractional abundance values were used to calculate the percentage of D₂O-labeled FcRn remaining in the system. FIGS. 11A and 11B show that FcRn turnover rates are similar between human vascular endothelial cells (HUVECs) and placental trophoblasts (HVTs). Furthermore, treatment with N027 did not change the FcRn turnover rates.

15

Example 15 – FcRn localization in target cells

The localization of N027 was compared in human vascular endothelial cells (HUVECs) and placental trophoblasts (HVTs). Cells were grown on glass coverslips in EBM-2/TM media. Live cells were incubated in media containing DyLight594-N027 (2 µg/mL) for 1 hour at 37 °C. Cells were then washed and imaged live on fluorescence microscope in confocal mode with 60X dry objective using appropriate filters. Representative single cell images show similar localization pattern of N027 bound to the endocytic pool of FcRn in both cell types (FIGS. 12A and 12B). The circle in the center of the cell indicates the location of the nucleus.

25

Example 16 – Effect of N027 treatment on dynamics of IgG trafficking: Intracellular IgG accumulation and co-localization with lysosomes

The effect of N027 treatment on dynamics of intracellular IgG accumulation was compared across FcRn expressing target cell types such as human vascular endothelial cells (HUVECs) and placental trophoblasts (HVTs). Cells were grown to confluence in EBM-2 media (Lonza, Waterville) or TM1 media (ScienCell). Confluent cell monolayers were then pulsed in 1 ml media containing either N027 (2 µg/ml) + VivoTag645-IgG (50 µg/mL) or isotype control IgG (2 µg/mL) + VivoTag645-IgG (50 µg/ml) for 20 hours at 37 °C. Cell monolayers were then washed and then chased for 0 min, 30 min, and 90 min at 37 °C in chase media containing either N027 (2 µg/mL) or Isotype control (2 µg/ml). After each chase period, cells were washed, detached, and collected by HyQtase treatment. Cell- associated VivoTag645-N027 was measured by flow cytometry. Values represent geometric mean fluorescence intensity (gMFI) ± SD (n=2). Cells treated with N027 showed higher levels of intracellular IgG. Further, the effect of N027 on the dynamics of intracellular IgG accumulation was similar between the two cells types tested as shown in FIGS. 13A and 13B.

40

We also determined whether N027 increases intracellular IgG and co-localization of IgG with

lysosomes in primary human umbilical vein endothelial cells (HUVECs). Cells were grown on glass

coverslips and incubated in media containing 10 µg/ml Alexa Fluor 594 Dextran (10,000 MW, anionic, fixable) for 2 hours at 37 °C. Following incubation cells were washed and pulsed at 37 °C for 20 hours in either N027 (2 µg/ml) + DyLight 488-IgG (50 µg/ml) containing media or Isotype control IgG (2 µg/ml) + DyLight 488-IgG (50 µg/ml) containing media; or in media without any IgG-treatments. The plates were 5 washed in cold media and then chased for 0 min or 30 min at 37 °C. The following chase conditions were used: the N027+DyLight 488-IgG pulsed set was chased in the presence of N027 (2 µg/mL); the Isotype+DyLight 488-IVIG pulsed set was chased in the presence of isotype control IgG (2 µg/mL) and the set without any IgG-treatments was chased in media only. Cells were washed, incubated in BD Cytofix/Cytoperm solution for 30 min at 4 °C in the dark, washed with perm wash buffer followed by 10 incubation in perm wash buffer + 10% normal mouse serum + 5 µg/ml mouse anti-human Lamp1 antibody for overnight at 4 °C in the dark. Cells were then washed with perm wash buffer and PBS, and then mounted on glass slides. Cell imaging was done using confocal mode on Olympus fluorescence microscope with a 60X dry objective with 2X optical magnification. As presented in FIGS. 13C and 13D, it was shown that N027 treatment increases the accumulation of IgG in the lysosomal compartment as 15 compared to isotype control IgG-treated cells.

Example 17 – Determination and Analysis of a structure of FcRn (a heterodimer comprised of FcRn/p51 and β2-microglobulin/p14) in complex with the N027 Fab

The complex of N027 Fab:FcRn was purified and concentrated to about 9 mg/ml in a buffer 20 composed of 30 mM HEPES (pH 7.5), 200 mM NaCl, 3% glycerol. This complex was set up in sitting drop vapor diffusion crystallization experiments. Drops consisting of 0.3 µl protein solution plus 0.3 µl reservoir solution were mixed over a reservoir of 80 µl of the reservoir solution. The plates were sealed and allowed to equilibrate at 4°C.

Plate-like crystals grew in several conditions over the course of 4 days to 7 weeks. The crystal 25 that ultimately led to the structure of the complex grew in a mother liquor consisting of 10% PEG 1000, 10% PEG 8000. The crystal was cryoprotected by soaking for about 2 minutes in a solution of 25% PEG 1000, 10% PEG 8000, 100 mM NaCl before mounting in a cryoloop and plunge-freezing in liquid nitrogen.

X-ray diffraction data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) 30 on beamline BL9-2, using a Dectris Pilatus 6M detector and a wavelength of 0.97946 Å. The diffraction images were processed to a resolution of 2.7 Å using HKL-2000 followed by various programs in the CCP4 (Collaborative Computational Project, Number 4) software suite. Details of data collection and processing are contained in Table 6.

The 2.7 Å structure of the N027 Fab:FcRn complex was solved by molecular replacement using 35 search models consisting of a complete FcRn (heterodimer of large and small subunits, p51 and p14, respectively) from Protein Data Bank (PDB) ID No. 4k71 and individual heavy and light chains of human Fab from PDB ID No. 5v7u with the program Phaser. There is one complete complex in the asymmetric unit with a solvent content of approximately 65%. The structure was subsequently completed and refined by successive rounds of manual building and real space refinement in the 40 program Coot followed by restrained refinement against the X-ray data using the program Refmac5 and

validation using the program Molprobity and various tools within Coot. The last several rounds of refinement in Refmac5 included TLS refinement with each chain defined as an individual TLS group. Details of structure solution and refinement are contained in Table 7.

Table 6

Parameter	Value*
Space group	C121
Unit cell parameters	
<i>a, b, c</i> (Å)	183.2, 67.6, 105.2
α, β, γ (°)	90.0, 104.9, 90.0
Resolution range (Å)	41.5-2.7 (2.75-2.70)
No. of reflections	115,072
No. of unique reflections	33,982
Completeness (%)	98.1 (96.4)
Multiplicity	3.4 (3.2)
$(I/\sigma(I))$	7.4 (1.0)
R_{merge} (%)	13.5 (75.7)
R_{pim} (%)	8.6 (48.2)
Overall B from Wilson plot (Å ²)	40.8

5

*values in parentheses are for the highest resolution shell

Table 7

Parameter	Value
Resolution range (Å)	41.5-2.7
Fraction of test reflections (%)	4.9
Final R_{work} (%)	21.5
Final R_{free} (%)	26.3
Mean B value (overall, Å ²)	28.6
R.m.s. deviations	
Bonds (Å)	0.01
Angles (°)	1.50
Ramachandran plot	
Most favored (%)	95.39
Allowed (%)	4.35
Outliers (%)	0.26

Structural Analysis of the FcRn epitope

The epitope of FcRn defined by the crystal structure is composed primarily of amino acids on the FcRn/p51 subunit but four amino acids from the β 2-microglobulin/p14 subunit are also involved. Overall, 5 the interaction between the N027 Fab and FcRn buries approximately 1020 \AA^2 , with 470 \AA^2 between the light chain and FcRn, 414 \AA^2 between the heavy chain and FcRn, and 136 \AA^2 between the light chain and β 2-microglobulin. All three CDR loops from both chains of the N027 Fab are involved in the paratope with CDR H2 and CDR L1 together contributing about half of the interacting amino acid with eight apiece. 10 CDRs H1, H3, and L2 contribute three amino acids each and CDR L3 contributes five. Three amino acids (KSG) at positions 66-68 Kabat in the light chain framework between CDRs L2 and L3 are also involved in binding. The epitope/paratope interface is fully defined by the electron density and has been fully modeled unambiguously. The Fab binding epitope on FcRn overlaps the canonical Fc binding site so tight binding by the FcRn antibodies is expected to block Fc binding. Additionally, the albumin binding site remains accessible. Additionally, a N-acetylglucosamine is present on Gln102 of FcRn that is well-defined by the electron density. An overview of the epitope as defined by the crystal structure is depicted 15 and are mapped onto the sequence in FIGS. 14-16. The W131 and Y88 residues on FCGRT appear to be the most significant residues that bind through H-bonding to the CDR L3 (YAGSGIY) and CDR H2 (R58) on the anti-FcRn N027 molecule.

20 **Example 18 – Suppression Of Endogenous Maternal And Fetal IgG In Cynomolgus Monkeys By N027 And Lack Of N027 Transfer To Fetal Circulation**

Pregnant female cynomolgus monkeys were dosed weekly from Gestation Day 45 (GD45) to C-section at GD100 (mid-gestation) or GD140 (late gestation). A cohort of animals was also included in the study that were allowed to deliver their infants (birth day [BD1]). The design study is depicted in Table 8.

25

Table 8: Study Design

Group No.	Test Material	Dose Level (mg/kg)	Dose Volume (mL/kg)	Dose Concentration (mg/mL)	No. of Females for C-section ^a		Live Birth BD1
					GD100 \pm 2	GD140 \pm 2	
1	Control	0	10	0	4	4	3
2	N027	100	10	10	4	4	-
3	N027	300	10	30	4	4	3

^a Twenty-four (24) pregnant females were initially enrolled on study (8 per group). Four pregnancies per group were assigned to the GD140 \pm 2 C-section cohort, and the remaining 4 pregnancies per group were assigned to the GD100 \pm 2 cohort.

IgG concentrations were measured in maternal and neonatal blood samples using a standard validated total IgG ELISA (Table 9). Briefly, polystyrene plates (96-well) were coated with commercially available anti-human IgG antigen. The coated plate(s) were washed to remove unbound sample and then blocked

using with blocking buffer followed by a wash to remove the residual blocking buffer. Serum samples were diluted and added to the anti-human IgG coated wells and incubated at room temperature for 60 ± 5 minutes. Each well was washed before addition of secondary (detection) antibody conjugated to horseradish peroxidase (HRP) and incubated at room temperature for 60 ± 5 minutes. Tetramethylbenzidine (TMB) substrate was subsequently added to each well and incubated at room temperature for 20 ± 5 minutes on a plate shaker, before addition of 2N H₂SO₄ to stop the enzymatic reaction. The absorbance of each well was read at 450 nm using the SpectraMax® 190 microplate reader. Any commercially available or proprietary pair of anti-human IgG capture antibody and HRP conjugated anti-human IgG detection antibody that recognizes total IgG and is cross-reactive with cynomolgus monkey IgG can be used to measure total cynomolgus monkey IgG in an ELISA. The IgG detection antibody can be, for example, intact IgG, polyclonal serum antibody, monoclonal antibody, or a Fab(2) fragment.

Table 9: Methods

Assay	Method
Total IgG ELISA	<ol style="list-style-type: none"> 1. Coat immunoassay plate with anti-human IgG. 2. Incubate with sample 3. Detect with HRP labeled and addition of TMB substrate
Receptor Occupancy by Fluorescence Activated Cell Sorting (FACS)	<ol style="list-style-type: none"> 1. Whole blood was treated with ammonium chloride to lyse RBC 2. Cells were spun, washed with PBS, stained with viability dye and incubated with Fc receptor blocking solution 3. Cells were washed with Perm/Wash buffer, suspended in buffer and incubated with fluor labeled N027 for 20 mins 4. Cells were then washed and resuspended in FACS buffer before analysis by FACS

15 For all pregnant adult females assigned to study, blood was collected by venipuncture from the femoral vein (preferred) or cephalic/saphenous veins according to Table 10. For all fetuses obtained by C-section on GD100 ± 2 or GD140 ± 2 , blood was collected from the umbilical cord according to Table 10. Samples (1 mL) were allowed to clot for at least 60 minutes; centrifuged and the resultant serum was 20 separated, transferred to appropriately labeled (e.g., IgG) polypropylene tubes, and frozen immediately in a freezer set to maintain -80°C.

Table 10: Sample Collection Timepoints for Evaluation

Gestation Day ^b	Time Points Relative to Dosing	Samples Collected
GD38±1 (prestudy)	Prestudy	Adult female: IgG
GD44-46 (first dose)	Predose	Adult female: IgG
GD44-46 (first dose)	Postdose: 2 hr	Adult female: IgG
GD44-46	Postdose: 4hr	-
GD45-47	GD45: 24hr	Adult female: IgG
GD47-49	GD45: 72hr	Adult female: IgG
GD48-50	GD45: 96hr	Adult female: IgG
GD51-53	GD52: Predose	Adult female: IgG
GD58-60	GD59:Predose	Adult female: IgG
GD65-67	GD66: Predose	Adult female: IgG
GD72-74	GD73:Predose	Adult female: IgG
GD79-81	GD80: Predose	Adult female: IgG
GD86-88	GD87: Predose	Adult female: IgG
GD93-95	GD94: Predose	Adult female: IgG
GD93-95 ^a	GD94: 2hr	Adult female: IgG
GD93-95 ^a	GD94: 4hr	-
GD94-96 ^a	GD94: 24hr	Adult female: IgG
GD96-98 ^a	GD94: 72hr	Adult female: IgG
GD97-99 ^a	GD94: 96hr	Adult female: IgG
GD100 ± 2 (1 st C-section cohort)	NA	Adult female: IgG; Fetus: IgG
GD100-102	GD101: Predose	Adult female: IgG
GD107-109	GD108: Predose	Adult female: IgG
GD114-116	GD115: Predose	Adult female: IgG
GD121-123	GD122: Predose	Adult female: IgG
GD128-130	GD129: Predose	Adult female: IgG
GD135-137 (last dose)	GD136: Predose	Adult female: IgG
GD135-137	GD136: 2hr	Adult female:IgG
GD135-137	GD136: 4hr	-
GD136-138	GD136: 24hr	Adult female: IgG
GD138-140	GD 136: 72hr	Adult female: IgG
GD139-141	GD136: 96hr	Adult female: IgG
GD140 ± 2 (2 nd C-section cohort)	NA	Adult female: IgG Fetus: IgG total
Day of parturition (Maternal: PPD1) (Neonate: BD1)	NA	Adult female: IgG Neonate: IgG

^a Time points were only collected from animals in the GD100 C-section cohorts.

^b Collection ranges listed based on potential dose days of GD44 to 46. All time points were based off of the dose day.

5 **Suppression of Endogenous Maternal IgG**

N027 administration resulted in dose-independent reductions in serum IgG levels in adult females beginning 72 hours postdose, and the greatest reductions in serum IgG concentrations were observed for both the 100 and 300 mg/kg dosed animals at the GD51-53: predose time point (FIG. 19). The serum IgG values for Group 2 (100 mg/kg) trended toward predose levels in a dose-dependent manner, 10 beginning at the GD65-67: predose time point and continuing until the next dose administrations on GD93-95 and GD135-137, after which, reductions of a similar magnitude were present within 72 hours of dosing. Group 3 animals (300 mg/kg) remained at a nadir IgG value at all pre-dose timepoints (as referred to in Table 10) throughout the dosing period. No change in IgG from baseline was observed in animals treated with vehicle (Group 1).

15 Dose-dependent increases in serum IgG concentrations were present 2 hours after dose administration on GD44-46, GD93-95, and GD135-137. These increases were likely the result of the detection of N027 by the total IgG assay and were not considered to be related to the pharmacology of N027. Dose-dependent reductions in fetal serum IgG levels were present relative to control values at the GD100 and GD140, and in neonates at the BD1 time point (FIG. 20).

20

Lack of N027 Transfer from Maternal to Fetal Circulation

The transfer of N027 from maternal circulation to fetal circulation was evaluated by measuring the level of N027 FcRn occupancy in fetal circulating monocytes. N027 receptor occupancy was assessed on monocytes, granulocytes, B-lymphocytes, and T-lymphocytes using a flow cytometric (FACS) assay to 25 measure the binding of fluorescent-labeled N027 to free/unbound FcRn in the presence and absence of saturating concentrations of N027. The unsaturated samples demonstrated the percentages of free or unbound FcRn receptor present on each leukocyte subset at each predose and postdose time point. The saturated samples were spiked with concentrations of unlabeled N027 that were determined to completely saturate any FcRn receptors that remained free/unbound at each postdose time point. N027 30 receptor occupancy was not detected in the whole blood of fetuses on day GD100 and GD140, or in neonates on BD1, in the context of the unsaturated sample analysis as described above.

Example 19 – Evaluation of the transplacental transfer of N027

Human placenta obtained from uncomplicated term pregnancies were utilized in an ex-vivo dual 35 perfusion single placental lobule method to evaluate the transplacental transfer of N027. Briefly, each placenta was examined for tears, and two chorionic vessels (one artery and vein) supplying a single intact peripheral cotyledon were cannulated with 3F and 5F umbilical catheters, respectively. The cotyledon was trimmed and placed in the perfusion chamber with the maternal surface upward. The intervillous space on the maternal side was perfused by two catheters piercing the basal plate. The flow rate of the 40 perfusate medium in the fetal and maternal circuits was 3.0 and 12 mL/min, respectively. The maternal

perfusate was equilibrated with a gas mixture made of 95% O₂ and 5% CO₂, and the fetal perfusate with a mixture of 95% N₂ and 5% CO₂. All experiments were carried out at a temperature of 37°C.

Each placental lobule was perfused for an initial control period of one hour to allow the tissue to stabilize to its new environment using an open-open configuration of the perfusion system. Perfusion was 5 terminated if one of the following occurred during the control period: a volume loss in the fetal circuit in an excess of 3 mL/h, or a pO₂ difference between the fetal vein and the artery less than 60 mmHg, indicating inadequate perfusion overlap between the two circuits. The control period was followed by an experimental period of four hours using a closed-closed configuration (i.e., re-circulation of the medium) 10 of the perfusion system. The latter was initiated by replacing the medium of the maternal and fetal reservoirs and the addition of 3 mg/ml of BSA.

The transfer of N027 across the human placental lobule was tested for three different 15 concentrations: 0.3 mg/ml, 3 mg/ml, and 30 mg/ml. Fourteen individual placentae were perfused for four hours with N027 being added to the maternal perfusate at 0.3 mg/ml, 3 mg/ml, and 30 mg/ml. Samples from the maternal artery and fetal vein, in 0.5 mL aliquots, were taken at 0, 15, 30, 60, 90, 120, 150, 180, 20 210 and 240 minutes during the experimental period. Antipyrine was employed as a positive control to validate the integrity of the circuits (FIGS. 17-18). Concentrations of N027 in maternal and fetal samples were determined using a sensitive meso scale discovery (MSD) immunoassay with a lower limit of quantification of 5 ng/ml. This assay involved a sandwich format using an anti-idiotypic antibody pair; wherein the MSD plate was coated with an anti-idiotypic Ab followed by incubation with sample and 25 revealed with the second biotinylated anti-idiotypic Ab followed by detection with MSD tagged streptavidin and addition of read buffer. The concentration of antipyrine was determined using a HPLC assay with UV detection at 260 nm after a liquid-liquid extraction. The mean fetal transfer rate for antipyrine across fourteen experiments was 41±2.8 %. The mean fetal transfer rate for N027 across fourteen experiments was 0.0027±0.0021% indicating very low levels of transfer. The results suggest that N027 could be used in methods of treating pregnant patients without causing fetal exposure.

OTHER EMBODIMENTS

While the disclosure has described specific embodiments, it will be understood that it is capable 30 of further modifications and this application is intended to cover any variations, uses, or adaptations of the disclosure following, in general, the principles of the disclosure and including such departures from the present disclosure come within known or customary practice within the art to which the disclosure pertains and may be applied to the essential features hereinbefore set forth.

All publications, patents, and patent applications are herein incorporated by reference in their 35 entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

Other embodiments are within the following claims.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of treating a fetal and neonatal alloimmune and/or autoimmune disorder comprising administering an anti-FcRn antibody to a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, wherein
 - the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
 - the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
 - the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
 - the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
 - the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
 - the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).
2. The method of claim 1, wherein the pregnant subject has a history of having had a previous fetus with a fetal and neonatal alloimmune and/or autoimmune disorder.
3. The method of claim 1 or claim 2, wherein the pregnant subject is at risk of having a fetus with a fetal and neonatal alloimmune and/or autoimmune disorder.
4. The method of any one of claims 1-3, wherein the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia, hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.
5. The method of claim 4, wherein the fetal and neonatal alloimmune and/or autoimmune disorder is hemolytic disease of the fetus and newborn.
6. The method of claim 4, wherein the fetal and neonatal alloimmune and/or autoimmune disorder is fetal and neonatal alloimmune thrombocytopenia.
7. The method of claim 4, wherein the fetal and neonatal alloimmune and/or autoimmune disorder is congenital heart block.
8. The method of any one of claims 1-7, wherein treatment reduces the risk of a miscarriage.

9. A method of treating fetal anemia associated with hemolytic disease of the fetus and newborn, comprising administering an anti-FcRn antibody to a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein
 - the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
 - the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
 - the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
 - the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
 - the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
 - the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).
10. The method of claim 9, wherein the method treats a fetus of the pregnant subject.
11. A method of treating fetal anemia associated with fetal and neonatal alloimmune thrombocytopenia in a pregnant subject, comprising administering an anti-FcRn antibody to a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein
 - the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
 - the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
 - the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
 - the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
 - the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
 - the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).
12. A method of treating fetal anemia associated with congenital heart block in a pregnant subject, comprising administering an anti-FcRn antibody to a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein
 - the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
 - the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
 - the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
 - the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
 - the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
 - the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).
13. A method of treating an autoimmune disorder, comprising administering an anti-FcRn antibody to a

pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

14. The method of claim 13, wherein the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

15. The method of claim 13 or claim 14, wherein the treatment reduces the risk of miscarriage.

16. A method of reducing the risk of developing an autoimmune or alloimmune disorder, comprising administering an anti-FcRn antibody to a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

17. The method of claim 16, wherein the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

18. The method of claim 16 or claim 17, wherein the treatment reduces the risk of miscarriage.

19. A method of decreasing antibody transport across the placenta of a pregnant subject, the method comprising administering an anti-FcRn antibody to the pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

20. A method of increasing antibody catabolism in a pregnant subject, the method comprising administering an anti-FcRn antibody to the pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),

the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

21. The method of claim 19 or claim 20, wherein the antibody causes a fetal and neonatal alloimmune and/or autoimmune disorder.
22. The method of claim 21, wherein the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.
23. The method of claim 19 or claim 20, wherein the antibody is an IgG antibody.
24. The method of any one of claims 1-23, wherein the light chain comprises a sequence having at least 90% identity to the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDAYYCSSLAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYLSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19).
25. The method of any one of claims 1-24, wherein the heavy chain comprises a sequence having at least 90% identity to the sequence of
EVQLLESGGGLVQPQGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRFT
TISRDN SKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).
26. The method of any one of claims 1-25, wherein the light chain comprises a sequence having at least 90% identity to the sequence of
QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDAYYCSSLAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI

SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and

the heavy chain comprises a sequence having at least 90% identity to the sequence of
EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

27. The method of claim 26, wherein the heavy chain comprises a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of SEQ ID NO: 24.

28. The method of claim 26 or claim 27, wherein the light chain comprises a sequence having at least 95%, 97%, 99%, or 100% identity to the sequence of SEQ ID NO: 19.

29. The method of any one of claims 1-28, wherein the light chain of the anti-FcRn antibody comprises the sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSYAGSGIYVFGTGTKVTLGQPKAAPSVTLFPPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSYSLTPEQWKSHKSYSQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19); and

the heavy chain of the anti-FcRn antibody comprises the sequence of

EVQLLESGGLVQPGGSLRLSCAASGFTFSTYAMGWVRQAPGKGLEWSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFCSVHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

30. Use of an anti-FcRn antibody in the manufacture of a medicament for the treatment of a fetal and neonatal alloimmune and/or autoimmune disorder in a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLV (SEQ ID NO: 1),

the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

31. The use claim 30, wherein the fetal and neonatal alloimmune and/or autoimmune disorder is selected from the group consisting of fetal and neonatal alloimmune thrombocytopenia, hemolytic disease of the fetus and newborn, alloimmune pan-thrombocytopenia, congenital heart block, fetal arthrogryposis, neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal anti-phospholipid syndrome, neonatal polymyositis, dermatomyositis, neonatal lupus, neonatal scleroderma, Behcet's disease, neonatal Graves' disease, neonatal Kawasaki disease, neonatal autoimmune thyroid disease, and neonatal type I diabetes mellitus.
32. Use of an anti-FcRn antibody in the manufacture of a medicament for the treatment of fetal anemia associated with hemolytic disease of the fetus and newborn in a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, wherein
 - the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
 - the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
 - the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
 - the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
 - the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
 - the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).
33. Use of an anti-FcRn antibody in the manufacture of a medicament for the treatment of fetal anemia associated with fetal and neonatal alloimmune thrombocytopenia in a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, wherein
 - the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
 - the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
 - the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
 - the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
 - the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
 - the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).
34. Use of an anti-FcRn antibody in the manufacture of a medicament for the treatment of fetal anemia

associated with congenital heart block in a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

35. Use of an anti-FcRn antibody in the manufacture of a medicament for the treatment of an autoimmune disorder in a pregnant subject, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLVS (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

36. The use of claim 35, wherein the autoimmune disorder is selected from the group consisting of alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Addison's disease, hemolytic anemia, autoimmune hepatitis, hepatitis, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatricial pemphigoid, limited scleroderma (CREST syndrome), cold agglutinin disease, Crohn's disease, dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Graves' disease, Hashimoto's thyroiditis, hypothyroidism, inflammatory bowel disease, autoimmune lymphoproliferative syndrome, idiopathic pulmonary fibrosis, IgA nephropathy, insulin dependent diabetes, juvenile arthritis, lichen planus, lupus, Ménière's Disease, mixed connective tissue disease, multiple sclerosis, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu arteritis, temporal arteritis, ulcerative colitis, uveitis, vitiligo, and Wegener's granulomatosis.

37. The use of any one of claims 30-36, wherein the light chain of the anti-FcRn antibody comprises a

sequence of

QSALTQPASVSGSPGQSITISCTGTGSDVGSYNLVSWYQQHPGKAPKLMYGDSERPSGVSNRFSGSKS
GNTASLTISGLQAEDEADYYCSSLAGSGIYVFGTGTKVTLGQPKAAPSRTLFFPSSEELQANKATLVCLI
SDFYPGAVTVAWKADSSPVKAGVETTPSKQSNKYAASSYSLTPEQWKSHKSYSQCQVTHEGSTVEK
TVAPTECS (SEQ ID NO: 19), and

the heavy chain of the anti-FcRn antibody comprises a sequence of


EVQLLESGGGLVQPGGLRLSCAASGFTFSTYAMGWVRQAPGKGLEWVSSIGASGSQTRYADSVKGRF
TISRDNSKNTLYLQMNSLRAEDTAVYYCARLAIGDSYWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGG
TAALGCLVKDYLPEPVTWSWNSGALTSGVHTFPAVLQSSGLYSLSSVTPSSLGTQTYICNVNHKPSN
TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
VDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24).

38. Use of an anti-FcRn antibody in the manufacture of a medicament for reducing the risk of developing an autoimmune or alloimmune disorder, wherein the anti-FcRn antibody comprises: (1) a light chain comprising a CDR L1, a CDR L2, and a CDR L3 and (2) a heavy chain comprising a CDR H1, a CDR H2, and a CDR H3, and wherein

the CDR L1 comprises the sequence TGTGSDVGSYNLV (SEQ ID NO: 1),
the CDR L2 comprises the sequence GDSERPS (SEQ ID NO: 2),
the CDR L3 comprises the sequence SSYAGSGIYV (SEQ ID NO: 3),
the CDR H1 comprises the sequence TYAMG (SEQ ID NO: 4),
the CDR H2 comprises the sequence SIGASGSQTRYADS (SEQ ID NO: 8), and
the CDR H3 comprises the sequence LAIGDSY (SEQ ID NO: 11).

IgG Competition

Anti-FcRn mAbs compete effectively for IgG (Fc) binding to FcRn at pH 6.0



	EC50 (nM)	N022	N023	N024	N026	N027
Human FcRn	2.93	2.48	2.48	3.24	3.25	
Cynomolgus FcRn	4.80	5.16	3.51	2.68	4.46	

FIG. 2 Human IgG Catabolism




FIG. 2 cont. Human IgG Catabolism






FIG. 2 cont. Human IgG Catabolism

FIG. 2 cont. Human IgG Catabolism








FIG. 3









56

FIG. 6





FIG. 7

Chronic ITTP Model






FIG. 8A




FIG. 8B

FIG. 8C




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10




FIG. 11A

Endothelial cells






FIG. 11B

Villous trophoblast cells



FIGS. 12A-12B



FIGS. 13A-13B





FIG. 13C

FIG. 13D





FIG. 14






FIG. 15

四
六
七
八

>NO27 Fab_Hc chain H (SEQ ID NO: 32)
EVVLEESGSLVQNGESSKSLSCASGFTTS [REDACTED] [REDACTED]
ADSVCKTFTGDSKSKVTLVOMSLRLLDQTAVYVCKR [REDACTED]
GDSVTEIAPSSKSTSCTTAACTCILKQVTEEVTTWMSMCLTSNTTAAVTOSSCLVS
LSSVTTWPSSESSSTOTYLCWMMKEWNLWVWVMEASCD
Crystal structure-determined
paratope is highlighted - HC

Crystal structure-determined paratope is highlighted - LC
VLSI/ECM/SI/SK/SV/CV/TC/ST/PT/CS
QHATCQASVSSPSSCSTTSCCTCIVV
surfaces, antigenic sites and coxsackievirus
Lysates, immunoprecipitates and immunoblots
VLSI/ECM/SI/SK/SV/CV/TC/ST/PT/CS

6

- Amino acids involved in "dimer" interface are lower case and underlined
- Bold amino acids have not been modeled in the crystal structure due to weak or absent electron density







FIG. 17

FIG. 18

N027 transfer at different concentrations







EIG. 20